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1. INTRODUCTION1, 32
Drugs are rarely administered as pure chemical substances alone and are almost always
given as formulated preparations or medicines. The development of dosage forms draws on
the discipline of biopharmaceutics, which integrates an understanding of formulations,
dissolution, stability, and controlled release (pharmaceutics); absorption, distribution,
metabolism, and excretion (pharmacokinetics, PK); concentration-effect relationships and
drug-receptor interactions (pharmacodynamics, PD); and treatment of the disease state
(therapeutics).  Drug is the substance used to cure, treat, restore the health state, or optimize
a malfunction. Formulation of a dosage form typically involves combining an active
ingredient and one or more excipients; the resultant dosage form determines the route of
administration and the clinical efficacy and safety of the drug. Optimization of drug doses is
also critical to achieving clinical efficacy and safety.
Various aspects of the drug converted into dosage forms:26
Transformation of drug into different dosage forms is done for the following reasons:
1. To protect the drug from oxidation (e.g. Vitamin C, Ferrous sulfate), hydrolysis (aspirin)
and reduction. e.g. coated tablets, sealed ampoules.
2. To protect the drug from destructive effect of gastric juice (HCL) of the stomach after
oral administration e.g. enteric coated tablets.
3. To provide a safe and convenient delivery of accurate dosage.
4. To conceal the bitter (e.g. chloramphenicol), salty or obnoxious taste or odour of a drug
substance e.g. capsules, coated tablets and flavoured syrups etc.
5. To provide for the optimum drug action through inhalation therapy. e.g. inhalation
aerosols and inhalants.
6. To provide for the drug into one of the body-cavities e.g. rectal suppositories.
7. To provide for the maximum drug action from topical administration sites. e.g. creams,
ointments, ophthalmic preparations and E.N.T. (ear, nose and throat) preparation.
8. To provide sustained release action through controlled release mechanism. e.g sustained
release tablets, capsules and suspensions.
9. To provide liquid dosage form of the drugs soluble in a suitable vehicle e.g. solutions.
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CLASSIFICATION OF DOSAGE FORMS:26
The general classification of dosage forms are:
DOSAGE FORM
Physical Route of Site of Use
State Administration Application
(i) Solid (i) Oral (i) Skin (i) Internal
(ii) Semisolid (ii) Parenteral (ii) Eye (ii)External
(iii) Liquid (iii) Rectal (iii) Tooth
(iv) Gaseous (iv) Nasal (iv) Hand
(v) Foot
(vi) Hair
(vii) Nose
Table No: 1
Classification according to route of administration
Route of
administration
Dosage forms
Oral Powders, tablets, capsules, solutions, emulsions, syrups, elixirs,
magmas, gels, cachets, pills.
Parenteral Solutions, suspensions, emulsions.
Transdermal Ointments, creams, powders, pastes, lotions, plaster
Rectal Suppositories, tablets, ointments, creams, douches, foams.
Urethral Suppositories
Sublingual Lozenges, tablets
Intranasal Solutions, sprays, inhalations.
Conjunctival Ointments
Intra-ocular Solutions
Intra-respiratory Aerosols
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ORAL DOSAGE FORMS:56
Oral dosage forms are the most frequently used route of administration among all routes.
Oral drug delivery is the most widely utilized route of administration among all the routes
that have been explored for systemic delivery of drugs via pharmaceutical products of
different dosage form. Oral route is considered most natural, convenient and safe due to its
ease of administration, patient acceptance and cost effective manufacturing process .Oral
route of drug administration has wide acceptance up to 50 to 60% of total dosage forms.
Solid dosage forms are popular and most preferred route due to its advantages. The most
popular dosage forms are being tablets.
TABLETS:20
Tablet is a pharmaceutical solid dosage form, comprising a mixture  of  active
substances  and  excipients,  usually  in  powder  form,  pressed or  compacted into a solid.
Tablets  dosage form is one of a most preferred dosage form all over  the world. In other
words, pharmaceutical tablets are solid flat or  biconvex disc’s prepared by compressing a drug
or a mixture of drugs, with or without diluents.
A tablet is usually a compressed preparation that contains:
 5-10% of the drug (active substance)
 80% of fillers, lubricants, glidants and binders
 10% of disintegrants and other compounds which ensure easy
disintegration, disaggregation and dissolution of the tablet in the stomach
or the intestine.
Advantages of  tablets:
1. They  are  unit  dosage  form  and  offer  the  greatest capabilities of all oral
dosage form for the greatest dose precision and the least content variability.
2. Cost is lowest of all oral dosage form.
3. Lighter and compact.
4. Easiest and cheapest to package and strip.
5. Easy to swallow with least tendency for hang-up.
6. Suitable for large scale production.
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Disadvantages of  tablets:
1. Difficult to swallow in case of children and unconscious patients.
2. Drugs with poor wetting, slow dissolution properties, optimum absorption
high in GIT may be difficult to formulate or manufacture as tablet that will
still provide adequate or full drug bioavailability.
3. Irritant effects on the GI mucosa by some solids.( eg: aspirin)
4. Possibility of bioavailability problems resulting from slow disintegration and
dissolution.
TYPES OF TABLETS:
a. Oral tablets for ingestion:
These tablets are meant to be swallowed intact along with a sufficient quantity of
potable water. Over 90% of the tablets manufactured today are ingested orally.
The various types of oral tablets for ingestion are:
1. Standard compressed tablets
2. Multiple compressed tablets
    a. Compression coated tablet
    b. Layered tablet
    c. Inlay Tablet
3. Modified release tablet
4. Delayed action tablet
5. Targeted tablet
      a. Floating tablet
      b. Colon targetting tablet
6. Chewable tablet
7. Dispersible tablet
b. Tablets used in the oral cavity:
The tablets under this group are aimed to release API in oral cavity or to provide local
action in this region. The tablets under this category avoids first-pass metabolism,
nauseatic sensations and gives rapid onset of action. The various types of tablets used
in the oral cavity are.
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1. Lozenges and troches
2. Sublingual tablet
3. Buccal Tablet
4. Dental cones
5. Mouth dissolving tablet
c. Tablets administered by other routes:
These tablets are administered by other route except for the oral cavity and so the
drugs are avoided from passing through gastro intestinal tract. The other types of
administered by other routes are.
1. Vaginal tablet
2. Implants
d. Tablets used to prepare solution:
The tablets under this category are required to be dissolved first in water or other
solvents before administration or application. This solution may be for ingestion or
parenteral application or for topical use depending upon type of medicament used.
The various types of tablets used to prepare solution are.
1. Effervescent tablet
2. Hypodermic tablet
3. Soluble tablet
TYPICAL MANUFACTURING PROCESS OF TABLETS:13
Traditionally, tablets have been made by granulation, a process that imparts two primary
requisites to formulate: compactibility and fluidity. Both wet granulation and dry granulation
(slugging and roll compaction) are used. Numerous unit processes are involved in making
tablets, including particle size reduction and sizing, blending, granulation, drying,
compaction, and (frequently) coating. Various factors associated with these processes can
seriously affect content uniformity, bioavailability, or stability.
The three process involved in the manufacturing of tablets are: Wet granulation,
Dry granulation, Direct compression.
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Table No: 2
Advantages and disadvantages of various methods of processing of tablets
S.No Process Advantages Disadvantages
1. Wet
Granulation
a) Increases and improves
the uniformity of powder
density.
b)  Improves cohesion
during and after
compaction.
c) Reduces air
entrapment.
a) It is an expensive process.
b).  Loss of material during
various stages of processing.
c) Stability may be major concern
for moisture sensitive or
thermoliable drug
2. Dry
Granulation or
slugging
a) It requires less
equipments and space.
b) Time consuming and
no need to dry the
content.
c) Slugging may be used
for moisture and heat
sensitive material.
a) It requires a specialized heavy
duty tablet press to form slug.
b) The process tends to create
more dust than wet granulation,
increasing the potential
contamination.
c) It does not permit uniform
colour distribution
3. Direct
compression
a) Cost effectiveness,
stability, Faster
dissolution, Simplified
validation.
a) Segregation, Low dilution
potential, cost, and lubricant
sensitivity
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Table No: 3
Steps involved in the manufacturing of tablets
Wet granulation Dry granulation Direct compression
1. Milling and mixing of drugs
and excipients
1. Milling and mixing of
drugs and excipients
1. Milling and mixing of
drugs and excipients
2. Preparation of binder solution 2. Compression into slugs or
roll compaction
2. Compression of tablet
3. Wet massing by addition of
binder solution or granulating
solvent
3. Milling and screening of
slugs and compacted powder
4. Screening of wet mass 4. Mixing with lubricant and
disintegrant
5. Drying of the wet granules 5.Compression of tablet
6. Screening of dry granules
7. Blending with lubricant and
disintegrant.
8. Compression of tablet
Manufacturing process:
1- Dispensing: (weighing and measuring)
Dispensing is the first step in any pharmaceutical manufacturing process. Dispensing is
one of the most critical steps in pharmaceutical manufacturing; as during this step, the
weight of each ingredient in the mixture is determined according to dose.
2- Sizing:
The sizing (size reduction, milling, crushing, grinding, pulverization) is an impotent step
(unit operation) involved in the tablet manufacturing. In manufacturing of compressed tablet,
the mixing or blending of several solid ingredients of pharmaceuticals is easier and more
uniform if the ingredients are approximately of same size. This provides a greater uniformity
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of dose. A fine particle size is essential in case of lubricant mixing with granules for its
proper function.
3- Powder blending:
The successful mixing of powder is acknowledged to be more difficult unit operation
because, unlike the situation with liquid, perfect homogeneity is practically unattainable.
4- Granulation:
Following particle size reduction and blending, the formulation may be granulated,
which provides homogeneity of drug distribution in blend.
5- Drying:
Drying is a most important step in the formulation and development of pharmaceutical
product. It is important to keep the residual moisture low enough to prevent product
deterioration and ensure free flowing properties. The commonly used dryer includes
Fluidized bed dryer, Vacuum tray dryer, Microwave dryer, Spray dryer, Freeze dryer, Turbo
- tray dryer, Pan dryer, etc.
6- Tablet compression:
After the preparation of granules (in case of wet granulation) or sized slugs (in case of
dry granulation) or mixing of ingredients (in case of direct compression), they are
compressed to get final product. The compression is done either by single punch machine
(stamping press) or by multi station machine (rotary press).
Figure No: 1 Diagrammatic representation of manufacturing process of tablets
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Figure No: 2 Flow chart of the manufacturing process of tablets
TABLET COATING:2,16
Tablet  coating is a common pharmaceutical technique of applying a thin polymer-
based film to a tablet  or a granule containing active pharmaceutical ingredients (APIs).
Coated tablets are defined as tablets covered with one or more layers of mixture of various
substances such as natural or synthetic resins ,gums ,inactive and insoluble filler, sugar,
plasticizer, polyhydric alcohol ,waxes ,authorized colouring material and sometimes
flavoring material .Coating may also contain active ingredient. Substances used for coating
are usually applied as solution or suspension under conditions where vehicle evaporates.
ACTIVE INGREDIENT
EXCIPIENT
MIXING AND
GRANULATION
DRYING
COMPRESSION
COATING
PACKAGING
INTRODUCTION
Department of pharmaceutics  Page 10
Advantages  of tablet coating:
I. Therapy:
a. Avoid irritation of oesophagus and stomach
b. Avoid bad taste
c. Avoid inactivation of drug in the stomach
d. Improve drug effectiveness
e. Prolong dosing interval
f. Improve dosing interval
g. Improve patient compliance
II. Technology:
a. Reduce influence of moisture
b. Avoid dust formation
c. Reduce influence of atmosphere
d. Improve drug stability
Disadvantages of tablet coating:
 Limitations of sugar coating such as relatively high cost, long coating time and
high bulk have led to the use of other coating materials.
 However the process of coating is tedious and time-consuming and it requires the
expertise of highly skilled technician.
Primary  Components  Involved  In  Tablet Coating:
The  primary components involved in tablet coating are.
1. Tablet properties
2. Coating process, design and control
3. Coating equipments
4. Parameters of the coating process
5. Facility and ancillary equipments
6. Automation in coating processes.
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Department of pharmaceutics  Page 11
COATING PROCESS:2,16
The coating may  be formed by a single application or may be built up in layers  through the
use of multiple spraying cycles. Rotating coating pans are often used for coating.  Uncoated
tablets are placed in the pan and the liquid coating solution is introduced into the pan while the
tablets are tumbling. The  liquid portion of the coating solution is then evaporated by passing
air  over  the  surface  of  the  tumbling  tablets.
The coating process is usually a batch operating task consisting of the following phases:
a. Identification of batch and Recipe selection (film or sugar coating)
b. Loading/Dispensing (accurate dosing of all required raw materials)
c. Warming
d. Spraying (Both application and rolling are carried out simultaneously)
e. Drying
f. Cooling
g. Unloading
Types of coating process:
Generally , There are three methods used for tablet coating are.
1. SUGAR COATING
2. FILM COATING
3. ENTERIC COATING
1- SUGAR COATING:
Compressed tablets may be coated with coloured or uncoloured sugar layer 30-50% size
also multi stage process
2- FILM COATING:
It is deposition of a thin film of polymer surrounding the tablet core (spray). Film coating is
more favored over sugar coating 2-3 % over all size, single stage process.
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Table No: 4
COMPARISION BETWEEN FILM COATING AND SUGAR COATING
TYPE FEATURES FILM COATING SUGAR COATING
Appearance Retain contour of
original core
Rounded with high
degree of polish
Weight increase because of
coating material 2 to 3% 30 to 50%
Tablet
Logo or ‘break lines’ Possible Not possible
Operator training required Automation and easy
training of operator Considerable
Adaptability to GMP High Difficulty may arise
Process stages Simple stage Multistage process
Process
Functional coatings For controlled release
products
Possible apart from
enteric coating
ENTERIC COATING:16,25
The word “enteric” indicates small intestine therefore enteric coatings prevent release of
medication before it reaches the small intestine. The enteric coated polymers remain unionise
at low pH, and therefore remain insoluble. But as the pH increases in the GIT, the acidic
functional groups are capable of ionisation, and the polymer swells or becomes soluble in
the intestinal fluid. Materials used for enteric coatings include CAP, CAT, PVAP and
HPMCP, fatty acids, waxes, shellac, plastics and plant fibers.
Definition:
An enteric coating is a barrier that controls the location of oral medication in the
digestive system where it is absorbed
Reasons for performing enteric coating:
The possible reasons are.
a. Protection of active pharmaceutical ingredients, from the acidic environment of the
stomach. (e.g. enzymes and certain antibiotics)
b. To prevent gastric distress or nausea from a drug due to irritation. (e.g. sodium
salicylate)
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c. For the delivery of drugs that are optimally absorbed in the small intestine to their
primary absorption site in their most concentrated form.
d. To provide a delayed-release component for repeat action.
e. Required for minimizing first pass metabolism of drugs
ENTERIC POLYMERS:17,18
Enteric polymers are designed to resist the acidic nature of the stomach contents, yet
dissolve readily in the duodenum. The mechanism by which enteric coating polymers
function is by a variable pH solubility profile where the polymer remains intact at a low pH
but at a higher pH will undergo dissolution to permit the release of the contents of the dosage
form.
Mechanism of drug release from enteric coating:
All enteric polymers posses ionizable acid groups, usually a free carboxylic acid from a
phthalyl moiety. The equilibrium between unionized insoluble polymer and ionized soluble
polymer will be determined by the pH of the medium and the pKa of the polymer. The
Henderson-Hasselbach equation can be used to predict the ratio of ionized to unionized
polymer based on these two parameters,
i.e.
pH- pKa= log   [Concentration ionized form/ Concentration unionized form]
Factors to be considered while selecting enteric polymer:
1. Polymer backbone and pKa
2. Plasticizers and opacifiers
3. Quantity/thickness of the enteric coating
4. Effect of film stability on enteric behavior of formulation
5. Coating process.
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Ideal properties of enteric coating material:
a. Resistance to gastric fluids
b. Susceptible/permeable to intestinal fluid
c. Compatibility with most coating solution components and the drug substrate
d. Formation of continuous film
e. Nontoxic, cheap and ease of application
f. Ability to be readily printed
ENTERIC COATING POLYMERS:
The various enteric coating polymers and their dissolution pH  are as follows.
 Cellulose acetate phthalate
 Polyvinyl acetate phthalate
 Shellac
 Methacrylic acid copolymers
 Cellulose acetate trimellitate
 Hydroxypropyl methylcellulose phthalate
Table No: 5
Different polymers and their dissolution pH
Polymers Dissolution pH
Shellac 7.0
Cellulose acetate phthalate (CAP) 6.2
Methacrylic acid copolymers 5.5-7.0
Cellulose acetate trimellitate (CAT) 5.0
Polyvinyl acetate phthalate (PVAP) 5.0
Hydroxypropyl methylcellulose phthalate (HPMCP) 4.5-5.5
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New materials used for tablet coating:
The various new materials used for tablet coating are.
a. Zein
b. Aqua-Zein, which is an aqueous zein formulation containing no alcohol.
c. Amylose starch and starch derivatives
d. Dextrins
TABLET DEFECTS:31
Tablet defects can come from any of the unit operation upstream and from the tablet
press. The raw materials may be of poor quality or do not meet specification, causing
excessive fines that lead to a host of defects. Tablet processing problems can be due to the
problem in the formulation or in the compression equipment, or both of them. The various
defects are.
I. Defects related to tabletting process:
a. Capping: It is partial or complete separation of the top or bottom of tablet due
air-entrapment in the granular material.
b. Lamination: It is separation of tablet into two or more layers due to air-
entrapment in the granular material.
c. Cracking: It is due to rapid expansion of tablets when deep concave punches
are used
II. Defects related to excipients:
a. Chipping: It is due to very dry granules.
b. Sticking: It is the adhesion of granulation material to the die wall.
c. Picking: It is the removal of material from the surface of tablet and its
adherence to the face of punch.
d. Binding: The problems of chipping, sticking and picking are due to the
amount of binder in the granules or wet granules.
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III. Defects related to more the one factor:
a. Mottling:  Due to a colored drug, which has different color than the rest of the
granular material, or  improper mixing of granular material, or  oil spots by
using oily lubricant.
IV. Defects related to machine:
a. Double Impression:  It is due to free rotation of the punches, which have
some engraving on the punch faces.
 V. Defects related to coating:
a. Blistering: It is local detachment of film from the substrate forming blister.
b. Picking: It is defect where isolated areas of film are pulled away from the
surface when the tablet sticks together and then apart.
c. Pitting: It is defect whereby pits occur in the surface of a tablet core without
any visible disruption of the film coating.
d. Blooming: It is defect where coating becomes dull immediately or after
prolonged storage at  higher temperatures.
e. Blushing:  It is defect best described as whitish specks or haziness in the
film.
f. Orange Peel/Roughness: It is surface defect resulting in the film being
rough and non-glossy. Appearance is similar to that of an orange.
g. Bridging: This occurs when the coating fills in the lettering or logo on the
tablet and is typically caused by improper application of the solution, poor
design of the  tablet embossing and improper atomization pressure.
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DISEASE PROFILE:
Constipation:6
Constipation (also known as costiveness or dyschezia) refers to bowel movements that
are infrequent or hard to pass. Constipation is a common cause of painful defecation.
Constipation can be acute, which means sudden and lasting a short time, or chronic, which
means lasting a long time, even years. Most constipation is acute and not dangerous.
Gastrointestinal (GI) tract:7
The GI tract is a series of hollow organs joined in a long, twisting tube from the mouth
to the anus. The movement of muscles in the GI tract, along with the release of hormones
and enzymes, allows for the digestion of food. Organs that make up the GI tract are the
mouth, esophagus, stomach, small intestine, large intestine which includes the appendix,
cecum, colon, and rectum and anus. The intestines are sometimes called the bowel. The last
part of the GI tract called the lower GI tract which consists of the large intestine and anus.
Figure No: 3
The lower Gastro intestinal  tract
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The large intestine absorbs water and any remaining nutrients from partially digested food
passed from the small intestine. The large intestine then changes waste from liquid to stool.
Stool passes from the colon to the rectum. The rectum is located between the last part of the
colon called the sigmoid colon and the anus. The rectum stores stool prior to a bowel
movement. During a bowel movement, stool moves from the rectum to the anus, the opening
through which stool leaves the body.
Bowel Control Work:7
Bowel control relies on muscles and nerves of the rectum and anus working together to
 Hold stool in the rectum
 Let a person know when the rectum is full
 Release stool when the person is ready
Circular muscles called sphincters close tightly like rubber bands around the anus until
stool is ready to be released. Pelvic floor muscles also help with bowel control.
Figure No: 4
The external and internal anal sphincter muscles
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Causes For Constipation:
Common causes  that lead to constipation are.
• Diets Low in Fiber:
Fiber is a substance in foods that comes from plants. Fiber helps stool stay soft
so it moves smoothly through the colon. Liquids such as water and juice help fiber to
be more effective.
• Medications:
Drugs like narcotics, calcium channel blockers, iron supplements, antidepressants,
antacids induces constipation.
• Life changes or daily routine changes:
During pregnancy, women may be constipated due to  hormonal changes or due
to uterus compresses the intestine. Aging can affect bowel regularity.
• Neurological and metabolic disorders:
Disorders like diabetes and hypothyroidism, disrupt the process the body uses to
get energy from food and spinal cord  injury,  parkinsonism, affect the brain and
spine.
• GI tract problems:
Some problems in the GI tract can compress or narrow the colon and rectum,
causing constipation. These problems include adhesions, diverticulosis, colon
polyps, tumours, celiac disease.
Symptoms:
Symptoms of constipation can include:
a. Infrequent bowel movements and/or difficulty having bowel movements
b. Swollen abdomen or abdominal pain
c. Pain
d. Vomiting
Diagnosis:
The diagnosis for constipation includes.
a. Medical history
b. Physical examination
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c. Diagnostic tests:
• Blood test
• Lower GI series
• Flexible sigmoidoscopy or colonoscopy
• Colorectal transit studies
• Anorectal function tests
• Defecography
Treatment:
Treatment for constipation depends on  the cause, severity, and duration of the
constipation and may include one or more of the following:
a. Changes in eating, diet, and nutrition
b. Exercise and lifestyle changes
c. Medication
d. Surgery
First-line treatments for constipation include changes in eating, diet, and nutrition;
exercise and lifestyle changes; and laxatives.
a) Changes in eating, diet, and nutrition:
The Academy of Nutrition and Dietetics recommends consuming 20 to 35 grams of
fiber a day for adults.
b) Exercise and lifestyle changes:
Engaging in daily exercise can help people with constipation. Another strategy is to
try to have a bowel movement at the same time each day. The best time is 15 to  45
minutes after breakfast because eating helps stimulate the colon.
c) Medication:
Medications like laxatives and enemas are recommended those people who have
not treated in diet and life style changes.
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NEUROGENIC BOWEL DYSFUNCTION:8,27
Neurogenic bowel dysfunction is the term used to describe dysfunction of the colon due
to loss of normal sensory and/or motor control or both as a result of central neurological
disease or damage. It leads to constipation, faecal incontinence and disordered defaecation.
Etiology:
It is common in spinal cord injury (SCI), brain injury, stroke, spina bifida, amyotrophic
lateral sclerosis, multiple sclerosis, sacral nerve injuries and diabetes mellitus, among
others.
Causes:
The digestion process is partly managed by messages sent between the brain and
digestive system. These messages are sent through nerves. When these nerves are damaged,
messages between the brain and digestive system are blocked. This prevents the bowels from
working properly. The spinal cord runs from the base of the brain to the lower back. There
are two main types of neurogenic bowel, depending on where along the spinal cord the
damage occurs.
Reflexic bowel:
This happens when there is damage around the neck or chest. Messages between the
colon (large intestine) and the brain are interrupted. As a result, a person may not feel the
need to have a bowel movement. However, stool is still building up in the rectum. The build-
up triggers a reflex causing the rectum and colon to react, leading to a bowel movement
without warning.
Areflexic bowel:
This happens when there is damage around the lower end of the spinal cord. When these
lower nerves are damaged, a person is unable to feel when he needs to have a bowel
movement. Also, the reflex may be reduced, so the rectum has a difficult time emptying
stool. This can lead to constipation.
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Symptoms:
The symptoms for the neurogenic bowel dysfunction may includes.
  Swollen abdomen
  Trouble having a bowel movement
  Abdominal pain
  Feeling full (not hungry) quickly
  Repeated bowel accidents
  Bleeding from the rectum
Treatment:
The treatment for the neurogenic bowel dysfunction may includes.
a. Bowel program
b. Medication:
  1. Stool softeners: eg. Dioctyl.
  2. Colonic stimulants: eg. Senna, Bisacodyl.
  3. Osmotic laxatives: eg. Polyethylene glycol, Lactulose.
  4. Bulk formers: eg. Ispaghula husk
c. Digital stimulation: Digital stimulation is done to encourage movement of the bowels
by stimulating the rectum.
d. Surgery: eg. Colostomy, Ileostomy.
LAXATIVES:14
Laxatives are agents which promote bowel evacuation. They may be misused and
overused. In excess, they may cause diarrhoea, dehydration, hypokalaemia, atonic bowel and
weight loss. Their use may be appropriate in certain situations e.g.
▪ If there is no response to dietary and lifestyle advice after approximately one month.
▪ If faecal impaction is present.
▪ If constipation or painful defaecation is associated with illness, post-surgery or
during pregnancy.
▪ In drug-induced constipation.
▪ If a patient has a pre-existing condition in which bowel strain is undesirable.
e.g. Coronary heart disease.
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Mechanism of action of laxatives:
Laxatives generally have been thought to act in one of the following ways.
1. Retention of intraluminal fluid, by hydrophillic or osmotic mechanism.
2. Decreased net absorption of fluid, by effects on small and large bowel fluid and
electrolyte transport.
3. Effects on motility by either inhibiting segmenting (non-propulsive) contractions or
stimulating propulsive contraction.
Classification of agents used for constipation:
1. Luminally active agents:
a. Hydrophillic colloids:
- Site of Action: Small and Large intestine.
- Bulk forming agents: Bran, Psyllium, Methyl cellulose, Sterculia.
b. Osmotic agents:
- Non absorbable inorganic salts
c. Stool- wetting agents:
- surfactants and emollients like mineral oil
2. Non Specific stimulants or irritants:
a. Diphenylmethanes: Biscodyl
b. Anthraquinones:  Cascara and senna
c. Castor oil
3. Prokinetic agents:
a. 5-HT4 receptor agonists
b. Opioid receptor antagonist
4. Faecal Softeners and Lubricants:
- Site of Action: - Small and Large Intestine.
a. Arachis Oil, Dioctyl sodium sulphosuccinate, Glycerine, Liquid Paraffin
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Table No: 6
Classification and Comparison of Representative Laxatives
Laxative effect and latency in usual clinical dosage
SOFTENING OF
FEACES
SOFT OR SEMIFLUID
STOOL
WATERY
EVACUATION
ONSET OF ACTION
1 TO 3 DAYS 6 TO 8 HOURS 1 TO 3 HOURS
Bulk forming laxatives:
 Bran
Psyllium
Methylcellulose
Surfactant laxatives:
  Docusates
  Polaxomers
Lactulose
Stimulant laxatives:
Diphenylmethanes: Biscodyl
Anthraquinone derivatives:
   Senna
   Cascara sagrada
Osmotic laxatives:
Sodium phosphates
Magnesium sulphate
Magnesim citrate
Milk of magnesia
Castor oil
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2. LITERATURE REVIEW
● Shrivastava Priyanka and Sethi Vandana., (2013), A Review article on:
Superdisintegrants. Disintegration plays a major role in improving the drug activity and
hence increases the patient compatibility. The therapeutic activity of the formulations is
obtained by disintegration followed by dissolution. Disintegrants are the substances that
causes the rapid disintegration of the capsules or tablets into smaller particles that dissolves
more rapidly than in the absence of the disintegrants. On the other hand super disintegrants,
as it name suggests superior to disintegrants  are the substances which facilitates or increases
the disintegration time even at low level ,typically 1-10% by weight relative to the total
weight of the dosage unit. This article comprises of study of superdisintegrants which are
being used in the formulation to provide safe and effective drug delivery with improved
patient compliance.
● Philip Butler and Thorsten Cech., (2013), EXCIPIENT UPDATE - Delivering Gastric-
Resistant Functionality Via a Colorless Top Coat. Several formulation development
challenges exist in the field of gastric-resistant film-coating. The functional polymer,
poly(methacrylic acid-co-ethyl acrylate) (MAE), can react with some pharmaceutical actives
(eg, omeprazole), and also with excipients (such as pigments or colourants) commonly used
in enteric coating formulation development. This work was initiated to investigate the
gastric-resistant functionality obtained by applying a clear, two-component MAE coating
formulation onto a tablet sub-coated with a pigmented instant-release coating. In a dry state,
MAE films inherently forms very brittle, non-tacky films due to its Tg of 113°C. As a result,
plasticizers are required for successful coating applications. The hydrophilic and lipophilic
plasticizers evaluated in this study reduced the Tg to only about 65-85°C, which is out of the
range of acceptable film-coating applications. Therefore, as fully functional MAE-based
gastric-resistant film-coatings are routinely formulated and coated at product temperatures of
less than 30°C, it's safe to assume that water acts as a plasticizer during the coating process
as well.
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● Kotha  Renuka et al., (2013), A Technical Review On Tablet Product Development.
The formulation of solid oral dosage forms, particularly tablets had undergone rapid change
and development over the last several decades due to  emergence of pre compression,
induced  die feeding, high speed and now ultrahigh speed presses, micro processor control
of precompression  ejection forces as  well as upper punch tightness on tablet presses.
The present review focuses on the General Considerations used in choosing the Tablet
Components, Additives, activities involved in tablet product design and designed
experiments that are used to investigate the process or product variables that systematically
influence  product quality and Validation of tablet products. It concluding that the  above
mentioned  prospects additional research and development and closure  cooperation among
the industries, universities and the  regulatory agencies are essential to define the properties,
the scope, and the use of pharmaceutical excipients in the  product  development approach
of Tablets
● Amit A. Patel et al., (2012), Formulation and evaluation of doxycycline hydrochloride
delayed release enteric coated tablets. The present study was undertaken with an aim to
formulate doxycycline hydrochloride delayed release tablets. Successful delivery of drugs
specifically to the intestine requires the protection of drug from being released in stomach.
This drug is universal antibiotic and can be targeted to the specific site of absorption by
enteric coating using pH dependant polymers. The present study demonstrates that the
doxycycline hydrochloride compression coated tablets could be targeted to intestine using
pH dependent polymers. Enteric coating was carried out using different polymers like
Eudragit L-30 D-55, hydroxy propyl methylcellulose phthalate, cellulose acetate phthalate
and acryl-EZE® to achieve 5% weight gain and 9 % weight gain. This was concluded that
formulation containing Eudragit L 30 D 55 remain intact in 0.1 N HCl and dissolve fast in
pH 6.8 phosphate buffer.and shows better results compare to the formulation containing
hypromellose phthalate and cellulose acetate phthalate.
● Ahuja Naresh et al., (2012), A review on development of  hpmcp based aqueous enteric
coating polymer. The advantages of an aqueous-based coating system have been recognized.
This is derived from the drawbacks of organic solvents, including pollution, explosion
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hazards and solvent toxicity. Especially, there are risks for operators. For these reasons,
water based systems are now gradually being applied instead of organic coating systems. The
objective of current study is to develop a HPMCP based enteric coating material which
satisfy the need of enteric coating and contains the advantages of aqueous coating material.
● Singh Deep Hussan et al., (2012), A review on recent advances of enteric coating.
Enteric coated tablets are solid unit dosage forms which are designed to bypass the stomach
and release the drug in small intestine and are meant for oral administration. The word
“enteric” indicates small intestine; therefore enteric coatings prevent release of medication
before it reaches the small intestine. Most enteric coatings work by presenting a coated
surface that is stable at the highly acidic pH found in the stomach, but breaks down rapidly at
a less acidic (relatively more basic) pH. Materials used for enteric coatings include CAP,
CAT, PVAP and HPMCP, fatty acids, waxes, shellac, plastics and plant fibers. The present
review describes enteric coating, their ideal properties, benefits and limitation, various
polymers used, their chemical structure, criteria for drug selection and mechanism, methods
of manufacturing and evaluation of enteric coated tablets.
● Patel Harshna and Solanki N S., (2012), Gastro Resistant Drug Delivery System:
A Review. The best new therapeutic entity in the world is of little value without an
appropriate delivery system. The most important role of a drug delivery system is to get the
drug ‘‘delivered’’ to the site of action in sufficient amount and the appropriate rate; however
it must also meet a number of other essential criteria. These include physical and chemical
stability, ability to be economically mass produced in a manner that assures the proper
amount of drug in each and every dosage unit and in each batch produced and as far as
possible patient acceptability. Enteric-coated dosage forms are designed to resist the acidic
environment of the stomach and to disintegrate in the higher pH environment of  the
intestinal fluid. The sub coating and enteric coating of the core tablets was done. Proton
pump inhibitors, H2 blockers, some NSAIDs, insulin delivery etc are suitable candidates for
developing delayed release dosage forms.
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● Tsung Yueh Tsai et al., (2011), Effect of diluents on the swelling force of the tablet.
The swelling force, especially the  swelling force development rate, is a very important
parameter in  studying the effect of a disintegrant in a tablet. However, a tablet also contains
diluents in most cases and the  effect of diluents on the swelling force has not been studied.
In this study two commonly used diluents,  microcrystalline cellulose and calcium phosphate
dihydrate, were investigated for their effect on the swelling  force with or without a
superdisintegrant, Polyplasdone XL. It was found that microcrystalline cellulose alone  can
develop swelling force depending on the compression force of the tablet. When combined
with Polyplasdone  XL, it can significantly change the swelling force of Poly plasdone XL.
Their results reveals that Depending on the nature, the diluent can display  the swelling force
or not. Di-tab doesn’t show any  swelling force but Avicel shows varied degrees of  swelling
force depending on the compression force.  Avicel alone shows gradual force development.
With  Di-tab added a plateau appears quickly.
● Ajit Patil et al., (2011), Formulation  and evaluation of enteric coated tablets for
azithromycin dihydrate to reduce the Gastrointestinal tract side effects.Three formulations
of core tablets were prepared and one whoshows rapid disintegration (below three minutes)
was selected for enteric coating . Enteric coat was employed by usingdifferent polymers
such as HPMC-55, Eudragit, Ethyl cellulose in different ratios Combination of  HPMC-55
and ethylcellulose (10:1.5) exibited better dissolution ,disintegration, hardness and friability
properties .This study concluded that enteric coated tablets of azithromycin dihydrate can
be prepared by using combination of polymers studied and we can reduce the GI tract side
effects.
● Nobutomo Ikarashi  et al., (2011), The Laxative Effect of Bisacodyl is attributable to
decreased aquaporin-3 expression in the colon induced by increased PGE2 secretion from
macrophages. This study was to investigate the role of aquaporin3 (AQP3) in the colon in the
laxative effect of bisacodyl. After oral administration of bisacodyl to rats, AQP3,
macrophages, cyclooxygenase 2 (COX2), and prostaglandin E2 (PGE2) were examined in
the colon. Aquaporins are integral membrane proteins from a larger family of major intrinsic
proteins (MIP) that form pores in the membrane of biological cells.Genetic defects involving
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aquaporin genes have been associated with several human diseases. From the results suggest
that bisacodyl may decrease the expression of AQP3 in the colon, which inhibits water
transfer from the luminal to the vascular side and leads to a laxative effect.
● AppaRao. B et al., (2010), Formulation and Evaluation of Aceclofenac Solid
Dispersions for Dissolution Rate Enhancement. Aceclofenac is a novel non-steroidal anti-
inflammatory drug (NSAID) having anti-inflammatory and analgesic properties, and  is
widely used in the treatment of rheumatoid arthritis, osteoarthritis, and ankylosing
spondylitis. One of the major problems with this drug is its low solubility in biological
fluids, which results into poor bioavailability after oral administration. Therefore, solid
dispersions (SDs) of Aceclofenac were prepared using lactose, mannitol and  urea to
increase its aqueous solubility. Aceclofenac SDs was prepared  in 9:1, 7:3 and 4:1 ratios
of the drug to polymer (by weight). In vitro release profiles of all SDs preparations were
comparatively evaluated and also studied against pure Aceclofenac. Faster dissolution was
exhibited by solid dispersion containing 9:1 ratio of drug: lactose. The increase in dissolution
rate of the drug may be due to increase in wettability, hydrophilic nature of the carrier and
due to reduction in drug crystallinity.
● Rupesh S. Kamble et al., (2010),  Formulation and Development Of Enteric Coated
Dosage Form Using Ketorolac Tromethamine to reduce the side effects while  prolonging
its action by using controlled release of oral dosage forms is highly  desirable. In the present
study direct compression method is used for the preparation of fabricated batches and
EudragitL100 is used as coating polymer for enteric  coating. In vitro release profiles of
batches F1-F4 shows that Ketorolac Tro methamine drug:polymer ratio with Guar gum,
Xanthan Gum, Ethyl cellulose and Sodium alginate give 79.32%, 91.52%, 88.35% and
92.19% drug release respectively in 12 hours. In vitro release profile of batches F5-F8 shows
85.21%, 95.52%, 93.50%, 97.24% respectively in 12 hours. In vitro release profile of
batches F9-F12 shows that Ketorolac Tromethamine in ratio 1:3 with Guar gum, Xanthan
Gum, Ethylcellulose and Sodium alginate gives release of 89.50%, 98.25%, 95.22%,
100.27% respectively in 12hours. And then showed higher increase in phosphate buffer
of  pH 6.0 up to 12 hours. All these batches follow near zero order kinetics. This indicates
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that the Guar Gum, Xanthan Gum and Ethyl cellulose and Sodium alginate at minimum
concentration is not only able to sustain but also control the drug release.
● Gushit, J. S et al ., (2010),  Overview of the Availability and Utilization of Kaolin as a
Potential Raw Material in Chemicals & Drugs Formulation in Nigeria. This work
reviewing the potentials of Kaolin as an essential natural occurring mineral raw material
employed in the formulation of chemicals, drugs and other medicinal applications. This
work is mainly  intended for exposing the researchers, chemists, pharmacists and
pharmaceutical industries to the availability of kaolin and benefits that could be derived
from optimally utilizing same in chemicals and drugs formulation as against the practice of
importing the processed kaolin for such purposes. From the study,  the properties of kaolin
indicates that the hydrophilic surface of kaolin allows it to be easily dispersed in water at
neutral pH of 6-8. The most preferred kaolin for pharmaceutical formulations is the finely
divided particles because they yield a very large surface area that adsorbs a wide variety of
compounds.
● Tansel Comoglu., (2010), Effects Of Compression Speed And Lubrication On The
Compaction Properties Of Some Commonly Used Direct Compression Materials.
This  study was to investigate the effects of punch speed and lubrication (with and without
the addition of 1% magnesium stearate) on the compaction properties of  three different
classes of excipients; microcrystalline cellulose (Avicel PH 101), pregelatinized starch
(Starch 1500) and dibasic calcium phosphate (Fujicalin) having plastic, elastic and brittle
fragmentation characteristics were evaluated. The three different speeds were investigated
10, 50 and 100 mm/sec. From the data observed, plastic materials like Avicel PH 101 form
harder tablets at low compression speeds whereas brittle fragmenting materials like Fujicalin
were relatively unaffected by compaction speed. Avicel PH 101 gave the hardest tablets at
all compression speeds with and without the addition of lubricant. It is concluded that
because of its plastic deformation under pressure, Avicel PH 101 perform as a binder
whereas both fragmentation and plastic deformation take place in Starch 1500.
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● V. P. Pandey et al,. (2009), Studies On Diluents For Formulation Of Tablets.
Tablet remains popular as a dosage form because of the advantages afforded both to the
manufacturer (e.g. Simplicity and economy of preparation, stability and convenience in
packing, shipping, and dispensing) and the patient (accuracy of dose, compactness, baldness
of taste and ease of administration). Tablet formulation may contain diluent to provide
better tablet properties such as improved cohesion, direct compression manufacturing and
to promote flow properties. In this study,  lactose monohydrate, dibasic calcium phosphate
(DCP) and microcrystalline cellulose phosphate (MCCP) were studied as diluents in the
same quantity for manufacture of chloroquine phosphate tablet using polyvinyl pyrrolidone
K-30 (PVP K-30) as binding agent and sodium starch glycolate (S.S.G.) as disintegrating
agent. It was concluded that formualtion containing lactose monohydrate as diluent produces
87.12% drug release in 45 minutes. So lactose monohydrate is considered as suitable diluent
for formulating this drug.
● Amitava Roy et al., (2009), Effects of plasticizers and surfactants on the film forming
properties of hydroxypropyl methylcellulose for the coating of diclofenac sodium tablets.
In this work, hydroxy propyl methyl cellulose (HPMC) 5cPs, an aqueous soluble polymer
was employed for coating diclofenac sodium (DFS) tablets 25 mg for protecting the integrity
of the drug yet rendering the drug to release at a faster rate on contact with the gastric
environment. The defect free selected formulations were further subjected for studying the
effects of surfactants like sodium lauryl sulphate (SLS) and Tween-80 along with the
plasticizers. The quality of the aqueous film coats or the plasticizer efficiency in case of
PEG-400 is in the order 1.5> 0.5> 1.0% and for PG 1 > 4 > 3% which can be stated on the
basis of less incidence of major coat defects like chipping, cracking,  orange peel,
roughness, blistering, blooming, picking. The quality of aqueous film coat or the surfactant
efficiency in case of SLS + PEG-400 is in the order 0.3< 0.5< 0.1% and SLS + PG is in the
order 0.5< 0.1< 0.3%. In case of Tween-80 +PEG-400 the order is 0.3 <0.5 < 0.1% and
Tween-80 + PG is in the order 0.3< 0.1< 0.5%. They concluding that tablet coating films
made of HPMC 5cPs with the addition of PEG at 1.5% and SLS at 0.3% and films made of
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HPMC 5cPs with PG at 1% and Tween-80 at 0.3% could be considered as an elegant
film forming formulation for solving different coating problems.
● Rajnikant C.Patel., (2009), Formulation  Strategies For Improving Drug Solubility
Using Solid Dispersions. The solubility is the biggest challenging aspects for most of the
drugs in develpoing the tablets. Solid dispersions have been employed to enhance the
dissolution rates of poorly water - soluble drugs. This work is based on the various solubility
enhancement strategies in solid dispersion. The approaches described are fusion (melting),
solvent evaporation, lyophilization (freeze drying), melt agglomeration process, extruding
method, spray drying technology, use of surfactant, electro static spinning method and
super critical fluid technology and also highlights the potential applications and limitations
of these approaches. They concludes  solid dispersion method is one of the effective
approaches to achieve the goal of solubility enhancement of poorly water-soluble drugs.
● T .S. Allagh et al., (2008), Drug distribution in granules: effect of diluent and  granule
size on the distribution of a hydrophilic low dose drug in granules.  Granules of  salbutamol
sulphate, a hydrophilic drug were prepared using three diluents: Maize starch, lactose and
a 50:50 binary mixture of maize starch and lactose to represent insoluble, soluble and
sparingly soluble diluents  respectively. Granules were prepared using wet granulation by
massing and screening  with 5%w/v gelatin solution as  binder. The dried granules were
subjected to sieve analysis and the concentrations of drug in the various granule sizes  were
determined. Both diluent type and granule size affected drug distribution in the granules
with the soluble diluent  giving the highest concentration of drug in the larger granules while
the insoluble and the sparingly soluble diluents  produced granules highest concentration of
drugs in the intermediate sized granules. Generally, the sparingly soluble diluent ensured
a more even distribution of hydrophilic drugs throughout the granule mass. It concludes that
soluble diluents  produced highest concentration of hydrophilic  drug in larger sized granules
and lowest  concentrations in the finer granules whereas  insoluble and sparingly soluble
diluents  produced granules with the highest  concentration of drug in the intermediate  sized
granules. Generally, the use of lactose and starch together as diluents produced more
uniform distribution of a hydrophilic drug in  the various granule sizes.
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● Nighat Razvi et al., (2005), The Effect Of Surfactant On The Dissolution Rate Of
Ibuprofen Tablets. The present study was conducted on the effect of surfactant on the
dissolution rate of ibuprofen tablets. The cationic (Cetyl Trimethyl bromide) and anionic
(Sodium dodecyl sulphate) surfactant present in the dissolution media have remarkable
effect on the dissolution rate of Ibuprofen. From the values observed, SDS at 0.5%
concentration in water shows drug release 97.61% in 60 minutes. So it was concluded that
maximum dissolution was obtained in the presence of anionic surfactant (Sodium dodecyl
sulphate) at  0.5% concentration of deionized water whereas non-ionic (Tween-80)
surfactant had little effect on the dissolution of Ibuprofen tablets
● Quintin Verloop et al., ( 2004), Compounded laxative formulations for substituting
phenolphthalein with sennosides A & B in solid dosage forms. This study was undertaken
to develop compounded formulations of laxative products containing the stimulant laxatives
sennosides A and B for the purpose of carcinogenicity occuring with the phenolphtahlein
and subesquent banned in several countries. The method of formulation is direct
compression and wet granulation method. Both DSC and HPLC confirmed no
incompatibilities in the dry mixtures. It is concluded that compatibility evaluation shows
that dry powder mixtures for filling capsules and for direct compression of tablets can thus
be used to formulate sennosides A & B into tablets.
● Kestur Gundappa Satyanarayana et al., (2004), Clay Surfaces- Fundamentals and
Applications. In this review, in case of solid dosage excipients clay minerals are classified
according to their functionality as excipient in solid dosage forms. Kaolinite is mainly used
as a diluent because of its white to greyish-white colour. Its suitability as pharmaceutical
excipient greatly depends on the geological nature (sedimentary, residual, and hydrothermal)
and mineral composition of the deposits, which have an important effect on texture and
particle size distribution, and consequently, on the rheological properties (flow) of the
powder mass. It is concluded that kaolin used as an diluent for tablet and capsule
formulations particularly for the immediate and modified release tablets dosage forms.
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● Eija Leskinen., (2003), Tablet disintegration: Effects of temperature and pH of aqueous
disintegrating fluid and influence of solubility of diluent on the behaviour of
superdisintegrants. In the experimental work three grades of lactose were combined with
foursuperdisintegrants and tablets were prepared with different porosity levels. Also one
hygroscopic and insoluble diluent, sorbitol and dicalcium  phosphate dihydrate were used
in combination with disintegrants. Disintegration and calorimetric measurements were
made in three temperatures with water and simulated gastric and intestinal fluid.
Investigations show that superdisintegrants have a greater effect on disintegration time in an
insoluble system than in a soluble or partially soluble system. It is concluded that results
showed that the choice of tablet excipients can have a great influence in disintegration time.
As the dissolution of drug is dependent on the disintegration rate of tablet, it is thus
important to pay attention to diluent and disintegrant  used in order to achieve the desired
availability for the drug.
● European Patent Specification., (1995), Bisacodyl Dosage Form: This subject invention
involves pharmaceutical compositions in dosage unit form, for peroral administration of
bisacodyl to a human or lower animal having a gastrointestinal tract, with a lumen there
through, with a small intestine and a colon with a junction there between, comprising:
(a) a safe and effective amount of rapidly-dissolving bisacodyl means; and
(b) a delivery means which completely surrounds and encases the bisacodyl means in the
dosage unit form prior to oral administration and which prevents the release of bisacodyl
from the dosage form into the lumen of the gastrointestinal tract during transport of the
dosage form through the lumen until the dosage form is near the junction between the small
intestine and the colon or in the colon, and which then releases the bisacodyl in the lumen
near the junction between the small intestine and the colon or within the colon.
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3. AIM AND OBJECTIVE
The aim of the present study is to design and formulate the enteric - coated tablets of
bisacodyl and to comply the physio- chemical properties as per BP limits.
● Bisacodyl is an highly acid liable and it is used as stimulant laxative drug that works
directly on the colon to produce a bowel movement. It is typically prescribed for relief of
constipation and for the management of neurogenic bowel dysfunction as well as part of
bowel preparation before medical examinations
To achieve these goal various prototype formulation trails were taken by wet granulation
method using different diluents and observing difference in the in-process parameters such
as dissolution, assay for complying the data as per BP limits under quality control.
The main objective of this study are:
1. To formulate the stable bisacodyl enteric coated tablets. To study the influence on
various diluents effects during compression of tablets.
2. To evaluate the formulated tablets  and to comply with the BP limits.
3. To study the release profile of the formulated enteric coated tablet and to compare
their drug release profile with the innovator product.
4. To perform stability studies for the optimized formulation for three months at
400C±20C, 75 % ± 5 % RH.
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4. PLAN OF WORK
The present work was carried out to formulate bisacodyl enteric- coated tablets and
to evaluate the in-vitro dissolution study  and stability studies for the prepared bisacodyl
enteric- coated tablets It was planned to carry out this study in the sequence below.
1. Literature survey
2. Preformulation studies
a. Evaluation of API’s
 Physical appearance
 Solubility
 Micrometric properties like Bulk density, Tapped density, Compressibility
index (%), Hausner’s ratio, Particle size distribution, Moisture content.
b. Drug- excipient compatibility studies.
 Physical observation.
 FT- IR studies
3. Formulation of granules by wet granulation method.
4. Evaluation of pre - compression studies for the final blend of all formulations
 Bulk density, Tapped density, Compressibility index, Hausner’s ratio,
sieve analysis and moisture content.
5. Compressing the core tablet under 8 station compression machine.
6. Performing the coating process for the core tablet by the pan coating method using
    enteric- coating polymer.
7. Evaluation of  enteric - coated tablets.
 Hardness, Thickness, Friability, disintegration test, in vitro dissolution
study, Drug content.
8. To perform stability studies for final optimized formulation.
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PLAN OF STUDY
Pre-Formulation  Studies
Raw material Evaluation
Formulation of Granules
Characterisation of Granules
Optimization of tablet formula
Compression of Tablets
Post- Evaluation of
Compressed tablets
(Uncoated)
Coating of compressed
uncoated tablets
Seal coating Enteric coating
Evaluation of Enteric coated
tablets
Stability Studies
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5.1 DRUG PROFILE34,54
Drug name: Bisacodyl
Synonym:
       4,4'-(Pyridin-2yl methylene) bis(phenyl acetate),  bisacodilo, 4,4'-(2-
Pyridylmethylene) bis(phenyl acetate).
Chemical Name: 4,4’-(2-Pyridylmethylene) di(phenylacetate)
Chemical Formula: C22H19NO4
Molecular weight: 361.39
Chemical structure:
Description:
        Bisacodyl is a hygroscopic diphenol. Bisacodyl is an over-the-counter stimulant
laxative that can be used in either oral or suppository form. Stimulant laxatives encourage
bowel movements by increasing the muscle contractions in the intestinal wall that propel
the stool mass.
Therapeutic Category : Catharatics and laxatives
PHYSICAL AND CHEMICAL PROPERTIES:
Physical State: White to off-white crystalline powder
Melting Point:  131 – 1350C
Solubility: Soluble in alcohol (slightly), ether (slightly), chloroform, and acetone.
                    Practically  insoluble in water.
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Uses:
♦ It is used as stimulant laxative to relieve occassional constipation.
♦ It is used for emptying the bowel prior to surgery or radiological examinations.
♦ It is also used for  the management of neurogenic bowel dysfunction.
Available forms:
Bisacodyl is usually available as 5mg tablets, 10 mg suppositories, or 5 mg pediatric
suppositories. It is also available as a 1.25 US fluid ounces (37 ml) prepackaged enema
containing a 10 mg delivered dose of liquid bisacodyl.
Dosage and Administration:
1.Oral:
Indication: Constipation:
Adult: 5-10 mg at night.
Child: >4 yr: 5 mg at night time.
2. Rectal
Adult: 10 mg suppository/enema admin in the morning.
Child: <10 yr: 5 mg in the morning.
3.Oral
Indication: Bowel evacuation.
Adult: Initially, 10-20 mg the night before the procedure followed by 10 mg
suppository admin rectally the next morning.
Child: >10 yr: Same as adult dose. 4-10 yr: 5 mg the night before the procedure
and 5 mg suppository admin rectally the following morning. .
PHARMACOLOGY:
Mechanism of action:
Bisacodyl acts locally in the gastro intestinal tract by stimulating enteric nerves to cause
colonic mass movements. It is also a contact laxative,  it increases fluid and NaCl secretion.
Action of bisacodyl on small intestine is negligible; stimulant laxatives mainly promote
evacuation of the colon.
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PHARMACOKINETICS:
a. Absorption:
Absorption of bisacodyl  is minimal following oral or rectal administration.
The compound bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), is formed in
the intestine by hydrolysis of bisacodyl where it gets absorbed into the blood
stream, and is conjugated and circulates as the inactive form (mainly as a
glucuronide derivative). Onset: Oral therapeutic dosages: evacuation is produced
in 6–12 hours. Rectally administered bisacodyl produces evacuation of the colon
within 15 minutes to 1 hour.
b. Distribution:
 Bisacodyl is distributed into the milk. The plasma protein binding was found to
be greater than 99%
c. Metabolism:
Bisacodyl is converted to bis(p-hydroxyphenyl)pyridyl-2-methane by intestinal
or bacterial enzymes. It takes place in the liver.
d.Excretion:
 Bisacodyl is mainly excreted in urine and faeces as glucoronide.
Table No: 7
Pharmacokinetic parameters of Bisacodyl
Parameters Data
Bioavailability 15%
Biological half life 16 hours
Metabolism Hepatic (CYP450-mediated)
Special Populations:
Hepatic Impairment:
No specific dosage recommendations for bisacodyl in hepatic impairment.
Minimally absorbed systemically following oral or rectal administration.
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Renal Impairment:
No specific dosage recommendations for bisacodyl in renal impairment.
Minimally absorbed systemically following oral or rectal administration.
Geriatric Patients:
No specific geriatric dosage recommendations for bisacodyl.
Drug – Drug interactions:
a. Milk or antacids:
May cause enteric coating of tablets to dissolve, resulting in gastric lining irritation
or gastric indigestion. Do not give antacids or milk within one hour of taking the
drug (enteric coated).
b. Special precautions for use in children:
The tablet form of bisacodyl is not recommended for children under 6 years old.
Adverse effects:
The most common side effects for bisacodyl includes
a. GI irritation, fluid and electrolyte loss, or diarrhea.
b. Short-term usage (at normal dosages) typically results in abdominal pain or
cramps, faintness, nausea/vomitting and mild abdominal discomfort.
c. Prolonged bisacodyl therapy can cause hypokalemia.
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INNOVATOR PRODUCT DETAILS:
Tablet strength: 5mg enteric coated tablet
S.NO CONTENTS DESCRIPTION
1. Brand name Dulcolax
2. Label claim Each enteric coated tablet contains 5mg bisacodyl
3. Manufacturer Boehringer Ingelheim
4. Dosage form Tablet
5. Physical
parameters:
Description
Hardness
Thickness
Average weight
5mg pale yellow, round, smooth, bicovex shaped tablets.
2 – 3 kg/cm2
3.31mm
93mg/tab with enteric coating
6. Shelf life 3years
7. Storage Store at room temperature between  25- 300C
8. Inactive
ingredients
Lactose monohydrate, Maize starch, Soluble maize starch,
Glycerol (85%), Magnesium stearate, Sucrose, Talc,
Acacia(powdered), Titanium dioxide,  Methacrylic acid-
methyl methacrylate copolymer (1:1), Methacrylic acid-
methyl methacrylate copolymer (1:2), Castor oil, Macrogol
6000, Yellow iron oxide. White bees wax, Carnauba wax,
Shellac
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5.2 EXCIPIENT PROFILE
DIBASIC CALCIUM PHOSPHATE, DIHYDRATE:35
● Non-proprietary Names:
BP: Calcium Hydrogen Phosphate
JP: Dibasic Calcium Phosphate Hydrate
● Synonyms:
Calcium hydrogen orthophosphate dihydrate, Calcium monohydrogen
phosphate dihydrate, Phosphoric acid calcium salt (1 : 1) dihydrate, Secondary
calcium phosphate , DI-TAB, Emcompress.
● Chemical Name: Dibasic calcium phosphate dihydrate
● Structural Formula:
● Empirical Formula: CaHPO4 .2H2 0
● Molecular Weight: 172.09
● Functional Category: Tablet and capsule diluent.
● Description:
Dibasic calcium phosphate dihydrate is a white, odorless, tasteless powder or
crystalline solid. It occurs as monoclinic crystals. It is commercially available in two
particle size grades that  is milled and unmilled or coarser grade materials.
● Typical properties:
♦ Density: 2.389 g/cm3
♦ Acidity/alkalinity:   pH = 7.4
♦ Melting point:  Dehydrates below 1000C
♦ Solubility:
Practically insoluble in ethanol, ether, and water; soluble in dilute acids.
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● Applications:
 It is widely used in tablet formulations both as an excipient and as a source of
calcium and phosphorus in nutritional supplements.
 It is also used in pharmaceutical products because of its compaction   properties,
and the good flow properties of the coarse grade material.
 It is abrasive and a lubricant is required for tableting that is 1% w/w of
magnesium stearate or 1% w/w of sodium stearyl fumarate is commonly used.
 It is  also used in toothpaste and dentifrice formulations for its abrasive properties.
● Stability and Storage:
Dibasic calcium phosphate dihydrate is a non-hygroscopic, relatively stable
material. However, under certain conditions the dihydrate can lose water of crystallization.
The bulk material should be stored in a well-closed container in a cool, dry place.
● Incompatibilities:
 Dibasic calcium phosphate dihydrate should not be used to formulate tetracycline
antibiotics.
 Dibasic calcium phosphate dihydrate is incompatible with aspartame, ampicillin,
indoemethacin, cephalexin, aspirin and erythromycin.
KAOLIN:36
● Non-proprietary Names:
BP: Heavy Kaolin
JP: Kaolin
● Synonyms:
Kaolinite , China clay, Bolus alba, Porcelain clay, White bole, E559.
● Chemical Name: Hydrated aluminum silicate.
● Structural Formula:
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● Empirical Formula: Al2H4O9Si2
● Molecular Weight: 258.16
● Functional Category:
Adsorbent, suspending agent, tablet and capsule diluent.
● Description:
Kaolin occurs as a white to grayish-white colored, unctuous powder free from
gritty particles. It has a characteristic earthy or claylike taste, and when moistened with
water it becomes darker in color and develops a clay like odor.
● Typical properties:
 Acidity/alkalinity:   pH = 4.0-7.5
 Hygroscopicity: At relative humidities between about 15–65%, the equilibrium
moisture content at  250C is about 1% w/w, but at relative humidities above
about 75%, kaolin absorbs small amounts of moisture.
 Solubility:
Practically insoluble in diethyl ether, ethanol(95%), water, other organic
solvents, cold dilute acids, and solutions of alkali hydroxides.
● Applications:
Kaolin is a naturally occurring mineral used in oral and topical pharmaceutical
formulations. In oral medicines, kaolin has been used as a diluent in tablet and capsule
formulations. It has also been used as a suspending vehicle. Therapeutically, kaolin has been
used in oral antidiarrheal preparations.
● Stability and Storage:
Kaolin is a stable material. Since it is a naturally occurring material, It may be sterilized
by heating at a temperature greater than 160 0C for not less than 1 hour. It should be stored in
a well-closed container in a cool, dry place.
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● Incompatibilities:
The adsorbent properties of kaolin may influence the absorption of other orally
administered drugs. Kaolin is incompatible with drugs amoxicillin, cimetidine, ampicillin,
digoxin, lincomycin, phenytoin, warfarin and tetracycline.
STARCH:37
● Non-proprietary Names:
BP: Maize starch, Potato starch, Rice Starch, Tapioca Starch, Wheat Starch.
JP: Corn Starch, Potato Starch, Rice Starch, Wheat Starch.
● Synonyms:
Amido, amidon, amilo,  amylum, maydis amylum, Melojel, oryzae amylum, pisi
amylum, solani amylum, tritici amylum.
● Chemical Name: Starch
● Structural Formula:
● Empirical Formula and Molecular Weight:
(C6H10O5)n where n = 300-1000.
● Functional Category:
Tablet and capsule diluent, tablet and capsule disintegrant,  tablet binder,
thickening agent.
DRUG- EXCIPIENT PROFILE
Department of pharmaceutics Page 47
● Description:
Starch occurs as an odorless and tasteless, fine, white to off-white powder. It consists of
very small spherical or ovoid granules or grains whose size and shape are characteristic for
each botanical variety.
● Typical properties:
 Acidity/alkalinity:   pH = 4.0-8.0 for aqueous dispersion.
 Density: 1.478 g/cm3
 Moisture content :
All starches are hygroscopic and absorb atmospheric moisture to reach the
equilibrium humidity. An approximate value of different starches at 50% relative
humidity were given, 12% for corn starch,  14% for pea starch, 18% for potato
starch,  14% for rice starch, 13% for wheat starch.
 Solubility:
Practically insoluble in cold ethanol (96%) and in cold water. Starch becomes
soluble in hot water at temperatures above the gelatinization temperature.
Starches are partially soluble in dimethylsulfoxide and dimethylformamide.
● Applications:
a. Starch is a versatile excipient used primarily in oral solid-dosage formulations where
it is utilized as a binder, diluent, and disintegrant.
b. Starch is used as a diluent for the  preparation of standardized triturates of colorants,
potent drugs, and herbal extracts, facilitating subsequent mixing or blending
processes in manufacturing operations.
c. Starch quantities of 3–10% w/w can act as an anti adherent and lubricant in
tabletting and capsule filling.
d. In tablet formulations, freshly prepared starch paste is used at a concentration of
3–20% w/w as a binder for wet granulation.
e. Starch is one of the most commonly used tablet disintegrants at concentrations of
3–25% w/w.
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● Stability and Storage:
Dry starch is stable if protected from high humidity. Starch is considered to be
chemically and microbiologically inert under normal storage conditions. Starch should be
stored in an  air tight container in a cool, dry place.
● Incompatibilities:
Starch is incompatible with strongly oxidizing substances. Colored inclusion compounds
are formed with iodine.
MICRO CRYSTALLINE CELLULOSE:38
● Non-proprietary Names:
BP: Microcrystalline Cellulose
JP:  Microcrystalline Cellulose
● Synonyms:
Avicel PH, Celex,  Cellulose gel,  Hellulosum microcristallinum,  Emcocel,
Ethispheres,  Fibrocel, Pharmacel, Vivapur.
● Chemical Name: Cellulose.
● Empirical Formula and Molecular Weight:
(C6H10O5)n where n = 220
● Functional Category:
Adsorbent, suspending agent, tablet and capsule diluent,  tablet disintegrant.
C
● Structural Formula:
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● Description:
Microcrystalline cellulose is a purified, partially depolymerized cellulose that occurs as
a white, odorless, tasteless, crystalline powder composed of porous particles.
● Typical properties:
 Acidity/alkalinity:   pH = 5.0 to 7.5
 Density: 1.512 to 1.668 g/cm3
 Melting point:  Chars at 260–2700C
 Solubility: Slightly soluble in 5% w/v sodium hydroxide solution. Practically
insoluble in water, dilute acids, and most organic solvents.
● Pharmaceutical applications:
Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a
binder/diluent in oral tablet and capsule formulations where it is used in both wet-
granulation and direct-compression processes.
Table No: 8
Uses of Microcrystalline cellulose with concentration in percentage(%)
● Stability and Storage:
Microcrystalline cellulose is a stable though hygroscopic material. The bulk material
should be stored in a well-closed container in a cool, dry place.
● Incompatibilities:
Microcrystalline cellulose is incompatible with strong oxidizing agents.
Use Concentration (%)
Adsorbent 20-90
Anti adherent 5-20
Capsule binder/diluents 20-90
Tablet disintegrant 5-15
Tablet binder/diluents 20-90
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POVIDONE:39
● Non-proprietary Names:
BP: Povidone
JP: Povidone
● Synonyms:
Kollidon, Plasdone, Polyvinyl pyrrolidione,  Povidonum,  PVP, 1-vinyl-2-pyrrolidinone
polymer.
● Chemical Name: 1-Ethenyl-2-pyrrolidinone homopolymer
● Structural Formula:
● Empirical Formula: (C6H9NO)n
● Molecular Weight: n = 2500–3,00,0000
Table No: 9
Different grades of povidone with approximate molecular weight
S.No K- value Approximate Molecular Weight
1. 12 2500
2. 15 8000
3. 17 10000
4. 25 30000
5. 30 50000
6. 60 400000
7. 90 1000000
8. 120 3000000
● Functional Category:
Disintegrant, dissolution enhancer. suspending agent,  tablet binder.
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● Description:
Povidone occurs as a fine, white to creamy-white coloured, odorless or almost
odorless, hygroscopic powder.
● Typical properties:
 Acidity/alkalinity:   pH = 3.0–7.0 (5% w/v aqueous solution)
 Density: 1.180 g/cm3
 Melting point: Softens at 1500C
 Moisture content:
Povidone is very hygroscopic, significant amounts of  moisture being
absorbed at low relative humidities.
 Solubility:
Freely soluble in acids, chloroform, ethanol (95%), ketones, methanol,
and water. Practically  insoluble in ether, hydrocarbons, and mineral oil.
● Pharmaceutical applications:
 Povidone is used in a variety of pharmaceutical formulations and also
primarily used in solid-dosage forms. Povidone solutions are used as binders
in wet granulation process.
 Povidone is used as a suspending, stabilizing, or viscosity-increasing agent
in a number of topical and oral suspensions and solutions.
Table No: 10
Uses of Povidone with Concentration in percentage(%)
Use Concentration(%)
Carrier for drugs 10-25
Dispersing agent 5
Eye drops 2-10
Suspending agent 5
Tablet binder, diluent, or coating agent 0.5-5
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● Stability and Storage:
Povidone darkens to some extent on heating at 1500C, with a reduction in aqueous
solubility. It is stable to a short cycle of heat exposure around 110–1300C. Since the powder
is hygroscopic, it should be stored in an airtight container in a cool, dry place.
● Incompatibilities:
Povidone is compatible in solution with a wide range of inorganic salts, natural and
synthetic resins, and other chemicals. It forms molecular adducts in solution with
sulfathiazole, sodium salicylate salicylic acid, phenobarbital, tannin, and other compounds.
CROSCARMELLOSE SODIUM:40
● Non-proprietary Names:
BP:  Croscarmellose Sodium
JP: Croscarmellose Sodium
● Synonyms:
Ac-Di-Sol,  Crosslinked carboxymethylcellulose sodium, Modified cellulose gum,
Pharmacel XL,  Primellose,  Solutab, Vivasol.
● Chemical Name: Cellulose, carboxymethyl ether, sodium salt, crosslinked.
● Structural Formula:
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● Functional Category: Tablet and capsule disintegrant.
● Description:
Croscarmellose sodium occurs as an odorless, white or greyish white powder.
● Typical properties:
 Acidity/alkalinity:   pH = 5.0–7.0 in aqueous dispersion.
 Density: 1.543 g/cm3
 Solubility:
Insoluble in water, although croscarmellose sodium rapidly swells to
4–8 times its original volume on contact with water.  Practically insoluble in
acetone, ethanol and toluene.
● Pharmaceutical applications:
 Croscarmellose sodium is used in oral pharmaceutical formulations as a
disintegrant for capsules, tablets and granules.
 Croscarmellose sodium may be used in both direct-compression and wet-granulation
processes.
 Croscarmellose sodium at concentrations up to 5% w/w may be used as a tablet
disintegrant, although normally 2% w/w is used in tablets prepared by direct
compression and 3% w/w in tablets prepared by a wet-granulation process.
Table No: 11
Uses of Croscarmellose sodium with Concentration in Percentage(%)
USE CONCENTRATION(%)
Disintegrant in capsules 10-25
Disintegrant in tablets 0.5-5.0
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● Stability and Storage:
Croscarmellose sodium is a stable though hygroscopic material. Croscarmellose
sodium should be stored in a well-closed container in a cool, dry place.
● Incompatibilities:
Croscarmellose sodium is not compatible with strong acids or with soluble salts of iron
and some other metals such as aluminum, mercury, and zinc.
SODIUM LAURYL SULPHATE:41
● Non-proprietary Names:
BP: Sodium Lauryl Sulphate
JP: Sodium Lauryl Sulfate
● Synonyms:
Dodecyl Alcohol Hydrogen Sulfate, Sodium Salt,  Dodecylsulfate Sodium Salt,
Sodium N-Dodecyl Sulfate, Sodium Laurilsulfate, Sodium Monolauryl Sulfate, SDS,
SLS.
● Chemical Name: Sulfuric acid monododecyl ester sodium salt (1 : 1)
● Empirical Formula: C12H25NaO4S
● Molecular Weight: 288.38
● Functional Category:
Anionic surfactant, detergent,  emulsifying agent, skin penetrant, tablet and capsule
lubricant, wetting agent.
● Description:
Sodium lauryl sulfate consists of white or cream to pale yellow colored crystals,
flakes, or powder having a smooth feel, a soapy, bitter taste, and a faint odor of fatty
substances.
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● Typical properties:
 Acidity/alkalinity:   pH = 7.0–9.5 (1% w/v in aqueous solution)
 Density: 1.07 g/cm3
 Moisture content:  Sodium lauryl sulfate is not hygroscopic and its moisture
content is ≤ 5%.
 Solubility:
Freely soluble in water, giving an opalescent solution. Practically  insoluble
in chloroform and ether.
● Pharmaceutical applications:
 Sodium lauryl sulfate is an anionic surfactant employed in a wide range  of non-
parenteral pharmaceutical formulations and cosmetics.
 It is an detergent and wetting agent effective in both alkaline and acidic conditions.
 In recent years it has found application in analytical electrophoretic techniques: SDS
(sodium dodecyl sulfate) polyacrylamide gel electrophoresis is one of the more
widely used techniques for the analysis of proteins
●  Safety:
 Sodium lauryl sulfate is widely used in cosmetics and oral and topical
pharmaceutical formulation.
 Repeated, prolonged exposure to dilute solutions may cause drying and cracking
of the skin; contact dermatitis may develop.
 Prolonged inhalation of sodium lauryl sulfate will damage the lungs.
●  Incompatibilities:
Sodium lauryl sulfate reacts with cationic surfactants, causing loss of activity even in
concentrations too low to cause precipitation. Sodium lauryl sulfate is incompatible with
salts of polyvalent metal ions, such as aluminum, lead, tin or zinc.
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COLLOIDAL SILICON DIOXIDE:42
● Non-proprietary Names:
BP: Colloidal Anhydrous Silica
JP: Light Anhydrous Silicic Acid
● Synonyms:
Aerosil, Colloidal silica, Fumed silica, Silica sol, Silicic anhydride, Silicon dioxide
fumed, Synthetic amorphous silica, SAS, Cab-O-Sil
● Chemical Name: Silica
● Empirical Formula: SiO2
● Molecular Weight: 60.08
● Functional Category:
Adsorbent, anticaking agent, emulsion stabilizer, glidant, suspending agent, tablet
disintegrant, thermal stabilizer, viscosity-increasing agent.
● Description:
Colloidal silicon dioxide is a submicroscopic fumed silica with a particle size of about
15 nm. It is a light, loose, bluish-white-colored, odorless, tasteless, amorphous powder.
● Typical properties:
 Acidity/alkalinity:   pH = 3.8–4.2 (4% w/v in aqueous dispersion)
 Density: 0.029-0.042 g/cm3
 Melting point:  16000C
 Solubility:
Practically insoluble in organic solvents, water, and acids, except
hydrofluoric acid; soluble in hot solutions of alkali hydroxide. Forms a
colloidal dispersion with water.
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● Pharmaceutical applications:
 Colloidal silicon dioxide is widely used in pharmaceuticals, cosmetics, and food
products.
 Colloidal silicon dioxide is also used to stabilize emulsions and as a thixotropic
thickening and suspending agent in gels and semisolid preparations.
 In aerosols, other than those for inhalation, colloidal silicon dioxide is used to
promote particulate suspension, eliminate hard settling, and minimize the clogging
of spray nozzles.
 Colloidal silicon dioxide is also used as a tablet disintegrant and as an adsorbent
dispersing agent for liquids in powders.
Table No: 12
Uses of Colloidal silicon dioxide with Concentration in Percentage(%)
USE CONCENTRATION(%)
Aerosols 0.5-2.0
Emulsion stablisers 1.0-5.0
Glidant 0.1-1.0
Suspending and thickening agent 2.0-10.0
● Stability and Storage:
Colloidal silicon dioxide is hygroscopic but adsorbs large quantities of water without
liquefying. Colloidal silicon dioxide powder should be stored in a well-closed container.
●  Incompatibilities:
Incompatible with diethylstilbestrol preparations
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MAGNESIUM STEARATE:43
● Non-proprietary Names:
BP: Magnesium Stearate
JP: Magnesium Stearate
● Synonyms:
Dibasic magnesium stearate,  Magnesium distearate,  Magnesium octadecanoate,
Octadecanoic acid, Magnesium salt, Stearic acid, Magnesium salt.
● Chemical Name: Octadecanoic acid magnesium salt
● Structural Formula:
[CH3 (CH2)16 COO]2Mg
● Empirical Formula: C36H70MgO4
● Molecular Weight: 591.24
● Functional Category: Tablet and capsule lubricant.
● Description:
 Magnesium stearate is a very fine, light white, precipitated or milled, impalpable
powder of low bulk density, having a faint odor of stearic acid and a characteristic
taste.
 The powder is greasy to the touch and readily adheres to the skin.
● Typical properties:
 Density: 1.092 g/cm3
 Melting range:  117-1500C
 Flowability: Poorly flowing, cohesive powder.
 Solubility:
Practically insoluble in ethanol, ethanol (95%), ether and water. slightly
soluble in warm benzene and warm ethanol (95%).
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● Pharmaceutical applications:
Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical
formulations. Magnesium stearate is primarily used as lubricant in capsule and tablet
manufacture at concentrations between 0.25% and 5.0% w/w. Magnesium stearate is
hydrophobic and may retard the dissolution of a drug from a solid dosage form; the lowest
possible concentration is therefore used in such formulations.
●  Incompatibilities:
Incompatible with strong acids, alkalis, and iron salts. Avoid mixing with strong
oxidizing materials.
ISOPROPYL ALCOHOL:44
● Non-proprietary Names:
BP: Isopropyl Alcohol
JP: Isopropanol
● Synonyms:
Dimethyl carbinol, IPA, isopropanol,  2-propanol,  sec-propyl alcohol,  rubbing alcohol.
● Chemical Name: Propan-2-ol
● Empirical Formula: C3H8O
● Molecular Weight: 60.1
● Functional Category: Disinfectant; solvent.
● Description:
Isopropyl alcohol is a clear, colorless, mobile, volatile, flammable liquid with a
characteristic, spirituous odor resembling that of a mixture of ethanol and acetone; it has a
slightly bitter taste.
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● Typical properties:
 Boiling point: 82.40C
 Melting range: 88.580C
 Flammability:  Flammable.
 Solubility:
Miscible with benzene, chloroform, ethanol (95%), ether, glycerin, and water.
Soluble in acetone; insoluble in salt
I
.● Pharmaceutical applications:
 Isopropyl alcohol is also used as a solvent both for tablet film-coating and for tablet
granulation.
 Isopropyl alcohol (propan-2-ol) is used in cosmetics and pharmaceutical
formulations, primarily as a solvent in topical formulations.
 Isopropyl alcohol has some antimicrobial activity  and a 70% v/v aqueous solution is
used as a topical disinfectant.
●  Safety:
 Isopropyl alcohol is widely used in cosmetics and topical pharmaceutical
formulations. It is readily absorbed from the gastrointestinal tract and may be slowly
absorbed through intact skin.
 Prolonged direct exposure of isopropyl alcohol to the skin may result in cardiac and
neurological deficits. In neonates, isopropyl alcohol has been reported to cause
chemical burns following topical application.
 Inhalation of isopropyl alcohol can cause irritation and coma.
●  Incompatibilities:
Isopropyl alcohol may be salted out from aqueous mixtures by the addition of sodium
chloride, sodium sulfate, and other salts, or by the addition of sodium hydroxide.
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HYDROXYPROPYL METHYLCELLULOSE:45
● Non-proprietary Names:
BP: Hypromellose
JP: Hypromellose
● Synonyms:
Benecel MHPC, hydroxypropyl methylcellulose, HPMC, hypromellosum,  Methocel,
methylcellulose propylene glycol ether, methyl hydroxypropylcellulose, Pharmacoat.
● Chemical Name: Cellulose hydroxypropyl methyl ether.
● Empirical Formula and Molecular Weight:
Molecular weight is approximately 10, 000–1,500, 00.
● Functional Category:
Coating agent, Controlled-release agent, Dispersing agent, Dissolution enhancer,
Emulsifying agent, Forming agent, Foaming agent, Granulation aid.
● Structural Formula:
● Description:
Hypromellose is an odourless and tasteless, white or creamy-white fibrous or
granular powder.
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● Typical properties:
 Acidity/alkalinity: pH = 5.0–8.0 for a 2% w/w aqueous solution.
 Melting point:  browns at 190-2000 C; chars at 225-2300C
 Glass transition temperature: 170-1800C
 Loss on drying : ≤5.0%
 Solubility:
Soluble in cold water; practically insoluble in hot water, chloroform, ethanol
(95%), and ether; but soluble in mixtures of ethanol and  dichloromethane and
mixtures of methanol.
● Pharmaceutical applications:
Solid oral dosage forms
i) As tablet binder in either wet or dry granulations
(2-5%w/w).
ii) High viscosity grades as matrix formers for
sustained drug release (10-80%w/w).
iii) Depending on viscosity grade, concentrations of 2-
20%w/w are used for film-forming solutions to coat
tablets.
iv) Lower viscosity grade – aqueous film coating.
v) Higher viscosity grade – Nonaqueous coating.
Liquid oral dosage forms As suspending or thickening agents at concentrations of
0.25 o 5.0%.
Ophthalmic preparations Thickening agent to vehicles for eye drops and artificial
tear solutions (0.45 to 1.0%).
Nasal preparations At a concentration of 0.1%.
Topical preparations As an emulsifier, suspending agent and stabilizing agent
in topical gels and ointments.
●  Incompatibilities:
Hypromellose is incompatible with some oxidizing agents. Since it is nonionic,
hypromellose will not complex with metallic salts or ionic organics to form insoluble
precipitates.
DRUG- EXCIPIENT PROFILE
Department of pharmaceutics Page 63
POLYMETHACRYLATES:46,52
● Non-proprietary Names:
BP: Methacrylic Acid–Ethyl Acrylate Copolymer (1 : 1), Methacrylic Acid–
Ethyl Acrylate Copolymer (1 : 1) Dispersion 30 per cent, Methacrylic Acid–
Methyl Methacrylate Copolymer (1 : 1), Methacrylic Acid–Methyl Methacrylate
Copolymer  (1 : 2) Polyacrylate Dispersion (30 per cent)
Ph.Eur: Methacrylic Acid - Methyl Methacrylate Copolymer (1:1), Methacrylic Acid -
Methyl Methacrylate Copolymer (1:2)
● Synonyms:
Acryl-EZE, Eastacryl, Eudragit, Kollicoat MAE, Polyacrylatis dispersion 30 per
centum, Polymeric methacrylates.
● Chemical Name: Poly(methacylic acid-co-methyl methacrylate) 1:1
● Molecular weight: Approx. 125,000 g/mol
● Functional Category: Film-forming agent; tablet binder; tablet diluent.
● Structural Formula:
● Description:
EUDRAGIT® L 100 are anionic copolymers based on methacrylic acic and methyl
methacrylate. It is a solid substance in form of a white powder with a faint characteristic
odour. The ratio of free carboxyl groups to the ester is approximately 1 : 1.
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● Typical properties:
 Acid value: 300-330
 True density: 0.831- 0.852 g/cm3
 Glass transition Temperature (Tg): >130°C (+/- 5°C)
 Solubility:
Powder form is soluble in alcohols and acetone and in 0.1N NaOH it gives
clear solution, when it is cloudy. Practically insoluble in ethyl acetate,
methylene chloride, petroleum ether and water.
● Pharmaceutical applications:
 Polymethacrylates are primarily used in oral capsule and tablet formulations as
film-coating agents.
 Eudragit L-100 is used as an effective and stable enteric coating material for
faster dissolution in the upper Bowel of intestine.
●  Stability and Storage:
Dry powder polymer forms are stable at temperatures less than 300C. Above this
temperature, powders tend to form clumps, although this does not affect the quality of the
substance and the clumps can be readily broken up. Dry powders are stable for at least 3
years if stored in a tightly closed container at less than 300C.
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TALC:47
● Non-proprietary Names:
BP: Purified Talc
JP: Talc
● Synonyms:
Hydrous magnesium calcium silicate, Hydrous magnesium silicate, Magnesium
hydrogen metasilicate, Powdered talc, Purified french talc, Talcum.
● Chemical Name: Talc
● Empirical Formula and Molecular Weight:
Talc is a purified, hydrated, magnesium silicate, approximating to the formula
Mg6(Si2O5)4(OH)4. It may contain small, variable amounts of aluminum silicate and iron.
● Functional Category:
Anticaking agent, glidant, tablet and capsule diluent, tablet and capsule lubricant.
● Description:
 Talc is a very fine, white to greyish-white, odorless, impalpable, unctuous,
crystalline powder. It adheres readily to the skin and is soft to the touch and
free from grittiness.
● Typical properties:
 Acidity/alkalinity:  pH = 7–10 (20% w/v aqueous dispersion)
 Moisture content: Talc absorbs insignificant amounts of water at 250C and relative
humidities up to about 90%.
 Solubility:
Practically insoluble in dilute alkalis and acids, organic solvents and
water.
I
● Pharmaceutical applications:
 Talc was once widely used in oral solid dosage formulations as a lubricant and
diluents.
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Table No: 13
Uses of talc with concentration in percentage(%)
USE CONCENTRATION(%)
Dusting powder 90.0-99.0
Glidant and tablet lubricant 1.0-10.0
Tablet and capsule diluent 5.0-30.0
● Stability and  Storage:
Talc is a stable material and may be sterilized by heating at 1600C for not less than
1 hour. Talc should be stored in a well-closed container in a cool, dry place.
TITANIUM DIOXIDE:48
● Non-proprietary Names:
BP: Titanium Dioxide
JP: Titanium Oxide
● Synonyms:
Brookite titanium dioxide, Hombitan FF-Pharma, Rutile titanium dioxide,  Tioxide,
titanic anhydride.
● Chemical Name: Dioxotitanium
● Empirical Formula: TiO2
● Molecular Weight: 79.88
● Functional Category:
Coating agent, Opacifier and Pigment.
● Description:
White, amorphous, odorless, and tasteless,  non hygroscopic powder.
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● Typical properties:
 Moisture content:  0.44%
 Solubility:
Practically insoluble in dilute sulfuric acid, hydrochloric acid, nitric acid,
organic solvents, and water. Soluble in hydrofluoric acid and hot concentrated
sulfuric acid. Solubility depends on previous heat treatment; prolonged heating
produces a less-soluble material.
● Pharmaceutical application:
 Titanium dioxide is widely used in confectionery, cosmetics, and foods, in the
plastics industry, and in topical and oral pharmaceutical formulations as a white
pigment.
 It is used as a white pigment and opacifier.
 In pharmaceutical formulations, titanium dioxide is used as a white pigment in
film-coating suspensions, sugar-coated tablets, and gelatin capsules.
●  Incompatibilities:
Owing to a photocatalytic effect, titanium dioxide may interact with certain active
substances, e.g. famotidine
PROPYLENE GLYCOL:49
● Non-proprietary Names:
BP: Propylene glycol
JP: Propylene glycol
● Synonyms:
1,2-Dihydroxypropane,  2-hydroxypropanol,  Methyl ethylene glycol, Methyl
glycol, Propane-1,2-diol, propylene glycolum.
● Chemical Name: 1,2-Propanediol
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● Structural Formula:
● Empirical Formula: C3H8O2
● Molecular Weight: 76.09
● Functional Category:
Antimicrobial preservative, solvent, stabilizer for vitamins, plasticizer.
● Description:
Propylene glycol is a clear, colorless, viscous, practically odorless liquid  with a
sweet , slightly acrid taste resembling that of glycerin.
● Typical properties:
 Boiling point: 1880C
 Density: 1.038 g/cm3
 Melting point: -590C
 Solubility:
Miscible with acetone, chloroform, ethanol   (95%),glycerin, and water.
soluble at 1 in 6 parts of ether; not miscible with light mineral oil or fixed
oils, but will dissolve some  essential oils.
● Pharmaceutical application:
Propylene glycol has become widely used as a solvent. Propylene glycol is used as a
plasticizer in aqueous film-coating formulations.
● Storage:
Propylene glycol is hygroscopic and should be stored in a well closed container,
protected from light, in a cool, dry place.
● Incompatibilities:
Propylene glycol is incompatible with oxidizing reagents such as potassium
permanganate.
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TRIETHYL CITRATE:50
● Non-proprietary Names:
BP: Triethyl citrate
USP-NF: Triethyl citrate
●  Synonyms:
Citric acid, Ethyl ester, Citroflex 2, Citrofol AI, TEC.
● Chemical Name: 2-Hydroxy-1,2,3-propanetricarboxylic acid triethyl ester
● Structural Formula:
● Empirical Formula: C12H2O7
● Molecular Weight: 276.29
● Functional Category: Plasticizer, Solvent.
● Description:
Triethyl citrate is a clear, odorless, practically colorless, hygroscopic liquid.
● Typical properties:
 Acid value: 0.02
 Solubility:
Soluble 1 in 125 of peanut oil, 1 in 15 of water. Miscible with ethanol
(95%), and propan-2-ol.
● Pharmaceutical application:
 It is used to plasticize polymers in formulated pharmaceutical coatings.
Triethyl citrate is also used as a direct food additive for flavoring, for solvency,
and as an surface active agent.
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● Incompatibilities:
Triethyl citrate is incompatible with strong alkalis and oxidizing materials.
QUINOLINE YELLOW LAKE:30
●  Synonyms:
CI Food Yellow 13.
● Chemical Name:
Disodium 2-(1,3-dioxo-2-indanyl)-6,8-quinolinesulfates,  Disodium 2-(2- quinolyl)-
indan-1,3-dionedisulfonates
● Empirical Formula: C18H9NNa2O8S2
● Molecular Weight: 477.38
● Structural Formula:
● Description:
It is yellow powder or granules in nature.
● Typical properties:
♦ Solubility:
It is soluble in water and sparingly soluble in ethanol
● Pharmaceutical application:
It is used as an coloring agent in pharmaceutical formulations.
● Storage:
It is stored in original container at ambient temperatures.
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6.1. MATERIALS AND INSTRUMENTS
Table No: 14
List of  Materials
S.No Name of Ingredients Category Manufacturer’s name
1. Bisacodyl (BP) Drug J.P.N Pharma, India PVT Ltd
2. Dibasic calcium phosphate Filler Rhodia
3. Kaolin Filler Shijiazhuang
4. Starch Filler Universal chem
5. Lactose anhydrous Filler Loba chem
6. Microcrystalline cellulose Filler  FMC Biopolymer- USA
7. Croscarmellose sodium Disintegrant FMC Biopolymer
8. Sodium lauryl sulphate Surfactant Loba chem
9. Povidone Binder Blagden speciality chemicals
10. Aerosil Glidant Wacker chemical corporation
11. Magnesium stearate Lubricant Kant health care
12. Isopropyl alcohol Vehicle Ranchem
COATING INGREDIENTS
13. HPMC 15 cps Film polymer Dow chemicals
14. Eudragit- l- 100 Enteric coating ploymer Evonik idustries
15. Triethyl citrate Plasticizer Morflex
16. Propylene glycol Plasticizer Fisher Scientific UK Ltd
17. Purified talc Anti- tacking agent Vijaya minerals
18. Quinoline yellow lake Colorant Vinayak corporation
19. Titanium dioxide Opaquant Kronos ltd
20. Purified water Vehicle Fourrts india, Chennai
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Table No: 15
List of Equipments/Instruments
S.No. Name of the Equipment Manufacturer
1. 8 station compression machine Accura, Ahmedabad
2. Electromagnetic sieve shaker EMS 8.
3. Friability test apparatus (ET-2) Electrolab, India.
4. Bulk density apparatus Campbell electronics, Thermonick.
5. Automatic Coating Machine (Neocota 15 A) Srimach, LTD
6. Hardness tester Monsanto.
7. Disintegration test apparatus (ED-2L) Electrolab, India.
8. Dissolution apparatus (Disso 2000) Lab India.
9. pH meter (Digital 7007) Lab india.
10. IR Moisture balance Citizen
11. Electronic weighing balance (AR 2140) Adventurer Mettler Toleda.
12. Digital Vernier Caliper Mitutoyo Corp., Japan.
13. Hot air oven Pathak electrical works.
14. Stability chamber Thermolab.
15. HPLC with PDA/Binary system Schimadzu Corp., Japan.
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6.2. METHODOLOGY
PRE FORMULATION STUDIES:15
The basic concept of preformulation involves that almost all drugs are marketed as
tablets, capsules or both. Prior to the development of these major dosage forms, it is
essential that pertain fundamental physical and chemical properties of the drug molecule and
other divided properties of the drug powder are determined. This information decides many
of the subsequent events and approaches in formulation development. This first learning
phase is known as preformulation.
Definition:
Preformulation is defined as the science of investigation of physio-chemical properties
of a drug substance alone and when combined with excipients. Based on the physio-
chemical properties, the drug delivery system can be designed. A thorough understanding
of these properties may ultimately provide a rationale for the formulation design, or support
the need for molecular modification.
Factors to be considered before starting preformulation studies:
a. The amount of drug available.
b. The physiochemical properties of the drug already known.
c. Therapeutic category and anticipated dose of compound.
d. The nature of information, a formulation should have or would like to have.
Classification of Preformulation Studies:55
Preformulation studies can be broadly classified into two classes:
 Fundamental properties.
 Derived properties.
The method and function characterization of fundamental and derived preformulation
studies were given in the table below.
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Table No: 16
Preformulation drug characterization in a structured program
Test Method/ function Characterization
1. Fundamental
1) UV spectroscopy Simple assay
2) Solubility Phase solubility/ purity
a) Aqueous Intrinsic & pH effect
b) pKa Solubility control , salt formation
 c) Salt Solubility, hygroscopicity & stability
d) Solvents Vehicles & Extraction
e) ko/ w Lipophillicity, structure activity
f) Dissolution Biopharmacy
3) Melting point DSC-polymorphism hydrate & solvent
4) Assay development UV, HPLC, TLC
5) Stability
In Solution Thermal, hydrolysis, pH
In solid state Oxidation, proteolysis metal ion
2. Derived
6) Microscopy Particle size and morphology
7) Bulk density Tablet and capsule formation
8) Flow properties Tablet and capsule formation
9) Compression properties Acid / excipient choice
10) Excipient compatibility Preliminary screen by DSC, Conformation
by TLC
Scope:
Use of preformulation parameters maximizes the chances in formulating an
acceptable, safe, efficacy and stable product and at the same time provides the basis for
optimization of drug product quality.
The present  work has been initiated with the prefomulation studies for the following
parameters. The evaluation parameters was done according to British pharmacopoeia.
METHODOLOGY
Department of pharmaceutics Page 75
Evaluation of Active pharmaceutical ingredient (API):
A. Physio - Chemical evaluation:
1. Description
2. Solubility analysis
3. Moisture content
4. Bulk density
5. Tapped density
6. Particle size determination
B. Drug- Excipient compatibility studies:
1. Physical appearance
2. FT-IR studies
A. Physio -  chemical evaluation:
1. Description:
A typical preformulation should begin with the description of the drug substance, that is
colour, odour and taste of the new drug and the results are tabulated in Table No:30. Some
of the terminologies suggested to describe the new drug substances are given below.
Table No: 17
Terminologies indicating the product characters
Colour Odour Taste
Off- white
Cream
yellow
Tan
Shiny
Pungent
Fruity
Aromatic
Sulfurous
Odourless
Acidic
Bitter
Bland
Sweet
Tasteless
2. Solubility analysis:55
Basically solubility is an important parameter for physio-chemical properties for
determining the systemic absorption and its therapeutic efficacy. The solubility of drug was
determined by dissolving the drug in the various solvent system like water, acetone,
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isopropyl alcohol and ethanol in 250ml beaker. The results were shown in Table No: 31.
The approximate solubilities of pharmacopoeial and national formulary substances are
indicated by the descriptive terms in accompanying given below.
Table No: 18
SOLUBILITY SPECIFICATIONS
Descriptive terms
Approximate volume of solvent in
milliliters per gram  of solute
Very soluble Less than 1
Freely soluble From 1 to 10
Soluble From 10 to 30
Sparingly soluble From 30 to 100
Slightly soluble From 100 to 1000
Very slightly
soluble
From 1000 to 10,000
3.Moisture content:
The moisture means ‘wetness’, which influences the chemical stability, dissolution rate
and polymer film permeation on storage under stability condition. The moisture content was
determined by the IR moisture balance by adding the  known quantity of drug say 1 gm was
weighed on the sample pan. The sample was dried until anhydrous at 60˚c by the use of IR
radiation. The percentage of moisture content of the drug can be determined as the end point
display when all the moisture in the sample has been removed by the radiation. The results
were shown in Table No: 32.
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4. Bulk density:21
The bulk density is the ratio between an given mass of a powder and its bulk volume.
It is expressed as g/ml. Weighed quantity of bisacodyl powder were transferred into a 50 ml
measuring cylinder without tapping during transfer the volume occupied by the powder was
measured. It is given by the formula. The results were shown in Table No: 33.
   Bulk density(Db)  = m
Vo
where,
m = Mass of powder.
Vo = Bulk volume of the powder.
5. Tapped density:21
Tapped density is achieved by tapping the measuring cylinder which contains the sample
for certain tapping’s mechanically. During tapping, particles gradually pack more efficiently,
the powder volume decreases and the tapped density increases. After observing the initial
volume of powder occupied in the 100ml measuring cylinder and then subjected to 50 tap’s
in the bulk density apparatus (Campbell, thermonik). After 50 tappings the final volume is
noted down and the results are tabulated. It is calculated by the formula. The results were
shown in Table No: 33.
  Tapped density (Dt) = m
Vt
where,
m = Mass of powder
Vt = Volume of the powder occupied after tapping
6. Particle Size Determination:3
In case of tablets, size influences the flow and the mixing efficiency of powders and
granules. Size of the particle also an important factor in stability. Fine materials are relatively
more open to attack from atmospheric oxygen, the humidity and interacting excipients than
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are coarse materials. The particle size determination is done by various methods like sieve
method, microscopic method, sedimentation technique, coulter counter technique and low
angle light scattering technique.
Particle size distribution of the drug was estimated by sieving method. The sieves are
stacked on top of one another in ascending order. The test powder, for example 10gm, was
placed on the top sieve. The sieves are tightly screwed  and subjected to agitation for 5
minutes. After agitation the weight of powder retained on each sieve was accurately
weighed. Percentage of powder retained on each sieve was calculated by using the following
formula. The results were tabulated in the Table No: 34.
 Percentage retained =
Powder retained on each sieve
 X 100
Initial weight
B. DRUG- EXCIPIENT COMPATIBILITY STUDIES:
Incompatibility between drug and excipient can alter stability and bioavailability of
drugs, thereby, affecting its safety and/or efficacy. Study of drug–excipient compatibility is
an important process in the development of a stable solid dosage form. Drug–excipient
compatibility testing at an early stage helps in the selection of excipient that increases the
probability of developing a stable dosage form. In the tablet dosage forms, the drug is in
intimate contact with one or more excipients, the latter could affect the stability of the drug.
The drug excipient compatibility studies was determined from the physical compatibility
studies and FT-IR studies.
I. Physical compatibility studies:
API was mixed well with all excipients in binary ratio in an mortar  and small portion of
this mixed powder was placed in a cleaned and dried vial. This vial was kept in stability
chamber at 400C ± 20C/ 75±5% RH for 2 weeks. Physical observation has been carried out
visually at the initial stage and after 2 weeks exposure to the stated conditions. The results
were tabulated in Table No:35.
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II. FT-IR compatibility studies:10,12,24,57
Physical compatibility studies were assured by FT-IR studies. In this, crude drug
sample, drug-polymer mixtures and the final formulation were chosen for the study.
Potassium Bromide pellet method was used in this study. Initially, potassium bromide was
powdered and dried in oven. Dried potassium bromide powder was mixed with little quantity
of each test  sample, thoroughly triturated in mortar and pestle. A portion of mixture was
compressed using IR pelletizing press. Then the KBr pellet was placed in sample holder of
FT-IR spectrophotometer. The spectra were recorded in the wave number region of 4000-
400cm-1. In each case,  the spectra was compared with the pure bisacodyl spectrum to detect
the interactions between drug and excipients. The analysed FT-IR spectra and interpretation
data for the drug sample and the drug- excipient mixtures were shown in the
Figure No:7,8,9,10,11,12,13,14 and  Table No: 36, 37, 38,39, 40, 41, 42 and 43 .
Table No: 19
Protocol for Drug-Excipient compatibility studies
S.NO DRUG AND EXCIPIENTS RATIO
1. Drug 1
2. Drug + DCP 1:1
3. Drug + Kaolin 1:1
4. Drug + Lactose 1:1
5. Drug + Starch 1:1
6. Drug + CCS 1:1
7. Drug+ PVP 1:1
8. Drug + SLS 1:1
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Formulation of bisacodyl enteric- coated tablet:
● Selection of process:
Micrometric studies has been carried out for the active ingredient,  bisacodyl. Based on
the results observed  it was concluded that the drug is not suitable for direct compression
method due to fine particle size and poor flow characteristics. So, the enteric coated tablet  of
bisacodyl was prepared by wet granulation technique. All the tablet ingredients was
accurately weighed as mentioned in Table No:20. The average weight of each core tablet
was  fixed initially 120 mg and that was changed to 100mg on further trials.
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Table No: 20
FORMULATION TRIAL BATCHES
FORMULATION CODES.NO INGREDIENTS
    (mg)
F1 F2 F3 F4 F5 F6 F7
1. Bisacodyl 5.1 5.1 5.1 5.1 5.1 5.1 5.1
2. Dibasic calcium
phosphate
0 10 15 19 19 19 19
3. Kaolin 13 18 15 25 18 18 4
4. Starch 32 30 26 0 20 20 24
5. Lactose anhydrous 40 40 27 20 0 27 37
6. Microcrystalline
cellulose
0 0 0 20 27 0 0
7. Croscarmellose
sodium
3 3 2 2 2 2 2
8. Lactose anhydrous 13 0 0 0 0 0 0
9. Sodium lauryl
sulphate
0 0 1 0 0 0.3 0.5
10. Povidone K-30 3 3 3 4 4 4 3
11. Isopropyl alcohol Q.S Q.S Q.S Q.S Q.S Q.S Q.S
12. Starch 5 6 4 2 2 2 2
13. Croscarmellose
sodium
6 5 2 3 3 3 3
14.  Colloidal silicon
dioxide
0.2 0.2 0.25 0.25 0.25 0.25 0.25
15. Magnesium stearate 0.2 0.2 0.25 0.25 0.25 0.25 0.25
Average weight 120mg 120mg 100mg 100mg 100mg 100mg 100mg
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Table No: 21
PERCENTAGE OF INGREDIENTS USED IN TRIAL BATCHES
FORMULATION CODES.NO INGREDIENTS
    (%)
F1 F2 F3 F4 F5 F6 F7
1. Bisacodyl 4.25 4.25 5.1 5.1 5.1 5.1 5.1
2. Dibasic calcium
phosphate
0 8.33 15 19 19 19 19
3. Kaolin 10.83 15.0 15 25 18 18 4
4. Starch 26.6 25.0 26 0 20 20 24
5. Lactose anhydrous 33.3 33.3 27 20 0 27 37
6. Microcrystalline
cellulose
0 0 0 20 27 0 0
7. Croscarmellose
sodium
2.5 2.5 2 2 2 2 2
8. Lactose anhydrous 10.83 0 0 0 0 0 0
9. Sodium lauryl
sulphate
0 0 1 0 0 0.3 0.5
10. Povidone K-30 2.5 2.5 3 4 4 4 3
11. Isopropyl alcohol Q.S Q.S Q.S Q.S Q.S Q.S Q.S
12. Starch 4.16 5 4 2 2 2 2
13. Croscarmellose
sodium
5 4.16 2 3 3 3 3
14. Colloidal silicon
dioxide
0.16 0.16 0.25 0.25 0.25 0.25 0.25
15. Magnesium
stearate
0.16 0.16 0.25 0.25 0.25 0.25 0.25
Average weight 120mg 120mg 100mg 100mg 100mg 100mg 100mg
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Manufacturing procedure:
Note: During all stages of the manufacturing process the temperature and humidity
shall be maintained at 250 ± 50C and 30 ±5% RH
Step 1: Weighing: Accurately weighed specified quantity of ingredients: Bisacodyl,  Kaolin,
Dibasic calcium phosphate, Starch, Croscarmellose sodium and Lactose anhydrous.
Step 2: Co-Sifting: The above  materials were co-sifted together by geometric dilution
method through #30 mesh and #60 meshes and placed in  a separate  polythene bag and they
are used as dry mix. [Note: Dry mix of formulations F1 to F4 were sifted by physical mixing
where as formulations F5 to F7 were milled and sifted through appropriate meshes.]
Step  3: Preparation of Binder solution :
Accurately weighed povidone is added to isopropyl alcohol and stirred well to get  a  clear
solution and this clear solution used as binder solution.
Step 4: Granulation: The sifted materials were mixed for 5 mins in a polythene bag before
granulating  and transferred  to  a vessel  and granulated with required quantity of binder
solution  by kneading method ( hand granulation ).
Step 5: Drying: The granules were dried in hot air oven at 40-500C . then semi dried
granules were passed through sieve No. 20, and continued the drying  till the  moisture
content of granules  is less than 1.0 %. Then after obtaining the optimum moisture content,
granules  were removed  from the oven.
Step 6: Sizing of  granules : The dried granules were sifted through #30 mesh to get
uniform particle size.
Step 7: Mixing & Lubrication: The above granules were mixed with croscarmellose
sodium. and  mixed well.  Finally lubricated with the  required quantity of colloidal silicon
dioxide and  magnesium stearate after sifting it through #60mesh for 2 mins.
Step 8: Compression: The lubricated granules was then compressed into tablets with an
average  weight 120 mg initially using  8.00 mm  punches.
Step 9: Seal coating
Step10: Enteric coating
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Figure No: 5
Formulation Flow chart of Wet Granulation Method for Trials F1 To F4
STEPS
DISPENSING
CO-SIFTING
Bisacodyl, Dibasic calcium
phosphate, Kaolin, Starch,
Lactose anhydrous, MCC,
CCS, SLS, Colloidal silicon
dioxide, Magnesium stearate
Bisacodyl, Kaolin,
Lactose anhydrous
DCP, CCS, SLS,
Starch.
30# mesh
60# mesh
MIXING
GRANULATION
DRYING AND
SIZING
LUBRICATION COMPRESSION
PACKING
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Figure No: 6
Formulation Flow chart Of Wet Granulation Method For Trials F5 To F7
STEPS
DISPENSING
CO-SIFTING
Bisacodyl, Dibasic calcium
phosphate, Kaolin, Starch,
Lactose anhydrous, MCC,
CCS, SLS, Colloidal silicon
dioxide, Magnesium stearate
Bisacodyl, CCS,SLS
Lactose anhydrous
DCP, Kaolin, Starch.
30# mesh
60# mesh
MIXING
GRANULATION
DRYING AND
SIZING
LUBRICATION COMPRESSION
PACKING
MILLING
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COATING FORMULA:
Seal coating:
Seal coating is important for preventing direct interaction between bisacodyl and
polymer. Seal coating is performed for the core tablet of formulation (F7). When 2% build
up is given, the weight of the seal coated tablet was found to be 102mg per tablet.
Table No: 22
Composition of  Ingredients for Seal Coating
S.No Ingredients Quantity( gm )
1 HPMC 15 cps 2.4
2 Talc 0.6
3 Titanium dioxide 0.6
4 Propylene glycol 0.4
    5. Purified water Q.S
Preparation of seal coating solution:
Weighed  accurately  a required quantity of HPMC  15 cps  and soaked in water for 30
mins, and  stirred until it swells. Mean while talc and  titanium dioxide was triturated in a
mortar and added to the above solution and stirred. followed by  propylene glycol as
plasticizer is added furtherly and stirred. Filter the above solution in #100 mesh. Finally the
volume were made up to the required quantity with purified water.
METHODOLOGY
Department of pharmaceutics Page 87
Enteric Coating:
Enteric coating is performed to protect the drug from acidic environment.
The seal coated tablets were subjected to enteric coating where the weight of the
enteric coated tablets was found to be 109.14mg when 7% build up is given.
Table No: 23
Composition of  Ingredients for  Enteric Coating
Preparation of  Enteric Coating solution:
A required quantity of Methacrylic acid copolymer powder, was weighed accurately
and kept stirring with the required quantity of water. Mean while, talc, titanium dioxide and
quinoline yellow lake were  triturated separately in a mortar until making a paste by adding
the water and added to the above solution and stirred. Filter the above solution with #100
mesh. Finally the volume were maked up to the required quantity with purified water.
S.No Ingredients Quantity ( gm )
1 Poly methacryllic acid -methyl acrylate(1;1) 7.854
2 Talc 2.142
3 Titanium dioxide 1.856
4 Triethyl citrate 1.856
6 Quinoline yellow lake 0.572
7 Purified water Q.S
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COATING PARAMETERS:
 Table No: 24
Operation condition for  Seal and Enteric Coating Process
Evaluation of pre compression parameter for powder blend:
The pre compression parameters for the powder blend or granules were evaluated  for
the following parameters. The results were tabulated in Table No: 43 and 44.
1. Bulk density
2. Tapped density
3. Compressibility index (%)
4. Hausner’s ratio
5. Moisture content
6. Particle size determination
Range
Specifications Seal coating Enteric  coating
Pan diameter 12” 12”
Speed of pan revolution 8-10 rpm 10-12 rpm
Distance of spray gun 5-6” 5-6”
Spray nozzle diameter 1.2 mm 1.2 mm
Spray rate 2.5-3 ml /min 1.5 -2.0 ml /min
Dry air temperature 50  ± 5/ 30 mins 50  ± 50C / 30 mins
Coating time 2 hours 4 hours
Bed temperature 30-400C 30-400C
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1. Bulk density:21
The bulk density is the ratio between an given mass of powder  and its bulk volume.
It is expressed as g/ml. Weighed quantity of granules were transferred into a 50 ml
measuring cylinder without tapping during transfer the volume occupied by the powder was
measured. It is given by the formula.
            Bulk density (Db)  = m
Vo
where,
m = Mass of powder.
Vo = Bulk volume of the powder.
2. Tapped density:21
Tapped density is achieved by tapping the measuring cylinder which contains the
sample for certain tapping’s mechanically. During tapping, particles gradually pack more
efficiently, the powder volume decreases and the tapped density increases. After observing
the initial volume of powder occupied in the 100ml measuring cylinder and then subjected
to 50 tap’s in the bulk density apparatus (Campbell, thermonik). After 50 tappings the final
volume is noted down and the results are tabulated. It is calculated by the formula.
  Tapped density (Dt)  = m
Vt
where,
m =  Mass of powder.
Vt = Volume of the powder occupied after tapping.
3. Compressibility index:28
. Compressibility is the ability of powder to decrease in volume under pressure using
bulk density and tapped density the percentage compressibility of powder were determined,
which is given as carr’s compressibility index. It is indirectly related to the relative flow rate.
Carr’s compressibility index was determined by the given formula.
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Compressibility index =
V0 – Vf
                                                           x 100
V0
where,
V0 = Unsettled apparent volume.
Vf = Final tapped volume.
Table No: 25
Carr’s Index
4. Hausner’s ratio:28
It is very important parameter to be measured since it affects the mass of uniformity of
the dose. It is usually predicted from hausner’s ratio and angle of repose Measurement
Hausner’s ratio related to interparticle friction and, as such could be used to predict powder
flow properties. Table No: 26 shows the flow description and corresponding hausner’s
ratio. It is determined by the formula.
Hausner Ratio  = V0
Vf
where,
V0 = Unsettled apparent volume.
Vf = Final tapped volume.
Compressibility index (%) Flow description
5-15 Excellent
12-16 Good
18-21 Fair
23-28 Passable
28-35 Poor
35-38 Very poor
>40 Very, very poor
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Table No: 26
Hausner’s ratio
Type of Flow Hausner’s ratio
Excellent 1.0– 1.11
Good 1.12 – 1.18
Fair 1.19 – 1.25
Passable 1.26 – 1.34
Poor 1.35 – 1.45
Very poor 1.46 – 1.59
Very, Very poor >1.60
5. Moisture content:28
The moisture means ‘wetness’, which influences the chemical stability, dissolution rate
and polymer film permeation on storage under stability condition. The moisture content
was determined by the IR moisture balance by adding the  known quantity of drug say 1 gm
was weighed on the sample pan. The sample was dried until anhydrous at 60˚c by the use of
IR radiation. The percentage of moisture content of the drug can be determined as the end
point display when all the moisture in the sample has been removed by the radiation.
6.Sieve analysis:3
The purpose of particle size analysis in pharmacy is to obtain quantitative data on the
size, distribution, and shapes of the drug and other components to be used in pharmaceutical
formulations. The particle size determination is done by various methods like sieve method,
microscopic method, sedimentation technique, coulter counter technique and low angle
light scattering technique.
Particle size determination of the drug was estimated by sieving method. The sieves are
stacked on top of one another in ascending order. The test powder, for example 10gm, was
placed on the top sieve. The sieves are tightly screwed  and subjected to agitation for 5
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minutes. After agitation the weight of powder retained on each sieve was accurately
weighed. Percentage of powder retained on each sieve was calculated by using the following
formula.
 Percentage retained =
Powder retained on each sieve
 X 100
Initial weight
Evaluation of Post Compression parameters for compressed tablets:
The compressed tablets were evaluated for the following parameters and The results were
tabulated in the Table No: 46 and 47.
1.General appearance
2. Hardness test
3. Thickness
4. Friability
5. Weight variation test
6. Disintegration test
7. Invitro dissolution study
1. General appearance:51
The  compressed tablets should be free from cracks, depression, pinholes etc. The colour
and polish of the tablets should be uniform on whole surface. The surface of the tablets
should be smooth. It is done by visual observation.
2. Hardness test:22
Tablets require certain amount of strength or hardness to withstand mechanical shocks
of handling in manufacture, packaging and shipping. Hardness can be defined as the
strength of the tablet to withstand the pressure applied. In this test, a tablet was laced
between two anvils, force was applied to the anvils and the crushing strength that just causes
the tablet to break is recorded. Hence hardness is sometimes referred to as “Crushing
Strength”.
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It was measured using Monsanto tablet hardness tester. The values were expressed in
kg/cm3.
3.Thickness:23
Tablet thickness is an important parameter to be controlled to facilitate packaging.
Tablet thickness, at constant compressive load, varies with changes in die fill, with particle
size distribution and packing of the particle mix being compressed. Tablet thickness must
be controlled within a ±5% variation of a standard value. The thickness of the tablets was
measured by using digital vernier calipers. The thickness was denoted in millimeter.
4. Friability:29
Friability is a measure of the resistance of the tablet to abrasion. The friability of
tablets was determined by using Roche friabilator. Tablets were weighed equivalent to 6.5g
and placed in friabilator and rotated at 100 revolution’s for 5 minutes. Then the tablets were
taken out, dedusted and reweighed. The percentage friability of the tablets were calculated
by the formula.
% Friability (F) = WO – Wf
x 100
Wf
Where,
WO = Initial weight of tablets
Wf = Final weight of tablets
5. Weight variation test:5
Weight variation test is performed to check that the manufactured tablets have an
uniform weight. Randomly weighed 20 tablets and calculated the average weight. Not more
than two of the individual weights deviate from the average weight by more than the
percentage deviation shown in table and more deviated by more than twice that percentage.
The percentage deviation of the tablets were calculated by the formula.
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Percentage deviation =
                                        Individual weight of tablet - Average weight of tablet
                                                                           x 100
 Average weight of tablet
Table No: 27
Weight variation table with percentage deviation
S.No Average weight
(mg)
Maximum percentage
deviation allowed (%)
1 130mg  or less ±10
2 130mg to 324mg ±7.5
3 More than 324mg ±5
6. Disintegration test:11
Disintegration is the first physical change observed for a drug when it enters into the
body, thus to see simulate the disintegration of the tablet in the body the disintegration test
is performed. The disintegration test for bisacodyl enteric coated tablets was carried out
using USP tablet disintegration tester about the temperature at 37oC±2˚C for 2 hours in
500ml 0.1N HCL ( pH 1.2), then the medium was changed to pH  7.4 phosphate buffer and
tested for 45 mins.
Table No: 28
Acceptance criteria for Enteric coated tablets
Type of tablet Medium Disintegration Time
0.1N Hydrochloric
acid (pH 1.2)
 Should not disintegrate in
120 mins
Enteric- Coated
tablets
Mixed phosphate
buffer(pH 7.4)
45mins
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7. In vitro dissolution studies:53
Dissolution at Acid stage medium:
• Apparatus: Type II paddle
• Speed: 100 rpm
• Duration: 2 hours
• Time points: Up to 2 hours
• Temperature: 37˚C ± 0.5˚C
• Medium: 500ml of 0.1N HCL
• Sample withdrawn: 10ml
Dissolution media Preparation:
Preparation of 0.1N HCL: 8.5 ml of concentrated HCL was added to 1000 ml of purified
water and the pH was adjusted to 1.2.
Standard Preparation : Accurately weighed and transferred 10.0 mg of bisacodyl in 100 ml
standard flask, add 5 to 10 ml 0.1N HCL to dissolve the drug completely and volume was
make up with  same medium up to 100ml. From this primary stock solution pipette out
10 ml  and transferred to 100 ml standard flask and made up the volume with 0.1N HCL
( pH 1.2) medium.
Dissolution procedure: Apparatus was set as per above conditions, one tablet was placed
in each of the six dissolution bowls containing 500ml of 0.1N HCL as medium and the
dissolution test was performed for  2 hours. An Aliquots of the dissolution medium was
withdrawn at  the specified time and filtered.
Sample injection procedure:
50 μl of sample preparation and standard preparation were injected into the liquid
chromatograph and recorded the chromatogram. The major peaks were recorded and
calculated for the assay quantity of bisacodyl in percentage from the peak areas of standard
and sample preparation and the percentage of bisacodyl drug released at the end of 2 hours
was calculated by the mentioned  formula.
BP limits :  NMT 5%  of the stated amount  of bisacodyl is dissolved in  2 hrs.
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Dissolution at Buffer stage medium:
• Apparatus: Type II paddle
• Speed: 100 rpm
• Duration: 45minutes
• Time points: 15, 30, 45 minutes
• Temperature: 370C ± 0.50C
• Medium: 900ml of phosphate buffer pH 7.4
• Sample withdrawn: 10ml
Dissolution media Preparation:
Preparation of phosphate buffer (pH 7.4): 7.80g of sodium dihydrogen orthrophosphate
in sufficient water to produce 1000ml. Add 5.0g of sodium dodecyl sulfate, heat to dissolve
and adjust the pH to 7.4.
Standard Preparation :
Accurately weighed and transferred 56.0 mg of bisacodyl in 100 ml standard flask, add
5 to 10 ml acetonitrile to dissolve the drug completely and volume was make up with the
same medium upto 100ml. From this primary stock solution pipetted out 10 ml and
transferred to 100 ml standard flask and made up the volume with pH 7.4 buffer medium.
Dissolution procedure:
Apparatus was set as per above conditions, one tablet was placed in each of the six
dissolution bowls containing  900ml of pH 7.4 as buffer medium and the dissolution test
was performed for 45 minutes. An Aliquots (10ml) of the dissolution medium was
withdrawn at the specified time points from each bowl and filtered through 5 μm filter paper.
Sample injection Procedure:
50 μl of sample preparation and standard preparation were injected into the liquid
chromatograph and recorded the chromatogram. The major peaks were recorded and
calculated for the assay quantity of bisacodyl in percentage from the peak areas of standard
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and sample preparation and the percentage of bisacodyl drug released at the end of
45minutes was calculated by the mentioned  formula
% Release =
                       AT              WS              1               900         98.15
-----      X ------    X ------    X ------  X -------   X  100
AS              100           100              5             100
where,
AT= Sample area
AS = Standard area
WS = Working standard
BP limits : NLT 75%  of the stated amount of bisacodyl is dissolved in 45mins.
 ASSAY BY HPLC METHOD:53
Chromatographic conditions:
The chromatographic conditions were set as per BP specifications.
Apparatus: HPLC
Column: A stainless steel column (25cm x 4.6mm) packed with
base- deactivated octadecylsilyl silica gel (5μm) usually
water’s symmetry (C18) is suitable.
Wavelength: 265nm
Flow rate: 1.5ml/min
Column temperature: Ambient
Detector: Photodiode array
Inject volume: 50μL
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Preparation of mobile phase:
A mixture of 45 volumes of acetonitrile and 55 volumes of 0.025M ammonium formate
previously adjusted to pH 5.0 with anhydrous formic acid.
Preparation of diluent:
A mixture of 4 volumes of glacial acetic acid, 30 volumes of acetonitrile and  66
volumes of distilled water was prepared as diluent for assay.
Preparation of phosphate buffer (pH 7.4):
7.80g of sodium dihydrogen orthrophosphate in sufficient water to produce 1000ml.
Add 5.0g of sodium dodecyl sulfate, heat to dissolve and adjust the pH to 7.4.
Preparation of standard solution:
50mg of bisacodyl RS  was accurately weighed and transferred into a 100ml clean dry
volumetric flask and dissolve in little  quantity of acetonitrile, sonicate for 5 minutes and
make up the volume. From this stock solution 5 ml was transferred into a 50 ml volumetric
flask and make up the volume with buffer medium.
Preparation of sample solution:
For the estimation in dosage form, 20 tablets were weighed and powdered. Amount
equivalent to 10 mg of bisacodyl from powdered tablets was accurately weighed and
transferred to 200 ml volumetric flask, added about 10 ml of acetonitrile mixture and
sonicate for 15 minutes. Cool the solution to room temperature and make up the volume
with same diluent. Filter a portion of above solution and pipette out 5 ml of the filtrate and
transferred to 50 ml volumetric flask and make up the volume with buffer.
Sample injection procedure:
20 µl of filtered portion of the standard preparation (five injections) and sample
preparation were separately injected into the chromatographic  system. The chromatograms
was recorded and the responses were measured for the major peaks. The content of
bisacodyl present in each tablet was calculated using the following expression.
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% Content =
AT  WS 5  50  P
------- X ------  X ----  X ------- X ----- X Avg.Wt X 100
AS           100  50 Spl Wt 100
where,
AS = Standard area
AT = Sample area
WS = Standard weight
Spl Wt = Sample weight
Avg.Wt = Sample average weight
Comparative Invitro dissolution profile study:9
In recent years, FDA has placed more emphasis on a dissolution profile comparison in
the area of post-approval changes and biowaivers. Under appropriate test conditions, a
dissolution profile can characterize the product more precisely than a single point dissolution
test. A dissolution profile comparison between pre-change and post-change products for
SUPAC related changes, or with different strengths, helps assure similarity in product
performance and signals bio in equivalence. Comparison of therapeutic performances of two
medicinal products containing the same active substance is a critical means of assessing the
possibility of alternative using between the innovator and any essentially similar medicinal
product. Dissolution profiles of two products can be considered similar by virtue of
 Overall profile similarity, and
 Similarity at every dissolution sample time point.
A simple model independent approach uses a difference factor (f1) and a similarity factor
(f2) to compare the dissolution profiles. The difference factor calculates the  percentage
difference between the two curves at each time point and is measurement of the relative
error between the two curves:
where, n is the number of time points, Rt is the dissolution  value of the reference batch at
time t and Tt is the dissolution value of the test batch at time t.
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The similarity factor f2 is a logarithmic reciprocal square root transformation of the sum of
squared error and is a measurement of the similarity in the percent dissolution between the
two curves.
General procedure:
i. Determine the dissolution profile of two products (6 units each) of the test and
reference products.
ii. Using the mean dissolution values from both the curves at each time interval,
calculate the difference factor (f1) and similarity factor (f2) using the above
equations.
iii. For curves to be considered similar, f1 values should be close to 0, and f2 values
should be close to 100. Generally, f1 values upto 15 (0-15) and f2 values greater
than 50 (50-100) ensures sameness or equivalence of the two curves.
The comparative dissolution study was performed to determine the similarity of dissolution
profiles for bisacodyl enteric coated tablets  between the innovator product (DULCOLAX)
with the optimized formulation. (F7) The results were tabulated in Table No: 50.
STABILITY STUDIES:19
Stability of a drug has been defined as the ability of a particular formulation, in a
specific container, to remain within its physical, chemical, therapeutics and toxicological
specifications throughout its shelf life.
Stability testing is used to:
 Provide evidence as to how the quality of the drug  product varies with time.
 Establish shelf life for the drug product.
 Determine recommended storage conditions.
 Determine container closure system suitability.
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Accelerated stability studies:
Generally the observation of the rate at which the product degrades under normal
room temperature requires a long time.  The International Conference of Harmonization
(ICH) Guidelines titled “Stability testing for new drug substances and product” (Q1A)
describes the stability test requirements for drug registration application in the European
Union, and United States of America. The accelerated stability was carry out by ICH
guidelines. The ICH guideline recommends the following storage conditions for stability
studies.
Table No: 29
STORAGE CONDITIONS FOR ACCELERATED STABILITY STUDIES
S.No. Study Storage Condition
1. Long term 25°C±2°C / 60%RH±5%RH
2. Intermediate 30°C±2°C / 65%RH±5%RH
3. Accelerated 40°C±2°C / 75%RH±5%RH
As per ICH guidelines, the samples for stability analysis must be exposed to an environment
of 40˚C±2˚C / 75% RH±5% RH for a period of 3  months. As per the standard protocol the
samples must be analysed at 0, 1, 2, and 3 months time points. Accelerated stability studies
were performed for the final enteric coated tablets. The tablets were packed in blister packing
material and loaded  into the stability chamber under 40±2˚C / 75% ±5% RH and the
samples were analyzed at 0, 1, 2 and 3 months time points.
Test Performed:
a. Test for physical parameters (description, hardness, thickness, friability,
disintegration).
b. Assay.
c. In vitro Dissolution Study.
The results of the stability studies are tabulated in Table No: 51 and 52. The data was
analyzed for any significant change in the values from the initial data.
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7. RESULTS AND DISCUSSION
PRE FORMULATION STUDIES:
Evaluation of Active pharmaceutical ingredient (API):
A. Physio -  Chemical evaluation:
1. Description:
Table No: 30 Description of bisacodyl
2.
Solubility analysis:
Table No: 31 Solubility analysis of bisacodyl
Inference:
Based on the solubility analysis, It is confirmed that the bisacodyl powder is only
soluble in solvents like acetone and isopropyl alcohol whereas it is insoluble in water.
Tests Specification Observation
Colour White to Off-white crystalline
powder
White crystalline powder
Odour Odourless Odourless
S.No Solvent Observation
1. Water Insoluble
2. Acetone Soluble
3. Isopropyl alcohol Sparingly soluble
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3. Moisture content:
Table No: 32     Moisture content of bisacodyl
Inference:
Based on the observed  value, the moisture content of bisacodyl was found to be with
in limits as specified
4. Micromeritic properties:
Table No: 33 Micromeritic properties  of bisacodyl
API Bulk density
 (g/ml)
Tapped
density
(g/ml)
Compressibility
Index
  (%)
Hausner’s
ratio
Moisture
 content
(%)
Bisacodyl 0.402±0.0005 0.519± 0.0003 21.49±0.001 1.29±0.0001 0.96%
Inference:
a. The bulk density of the powder was found to be 0.402gm/ml
b. The tapped density of the powder was found to be 0.519gm/ml.
c. The compressibility Index was found to be 21.49% indicating fair flow properties.
d. The hausner’s ratio was found to be 1.29 and the observed value indicates that the
powder shows moderate flow properties.
e. The moisture content was found to be 0.96% at 600C.
Based on the above results, it was concluded that this drug is not suitable for formulating the
tablets by direct compression method due to fine particle size and moderate flow in nature.
S.No Limits Observation
1. NMT 2% 0.96% at 600C
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5. Particle size determination:
Table No: 34 Particle size determination of bisacodyl
Sieve No.
(#)
Sieve aperture
 (μm)
Quantity weight
retained
(gm)
Cumulative
weight retained
(gm)
% Retained
20 850 μm 0.35 0.35 2.33
40 425 μm 0.86 1.21 8.055
60 250 μm 3.15 4.36 29.028
100 150 μm 4.25 8.61 57.323
Pan …. 6.35 14.96 99.60
Initial weight of powder = 15.02g
Final weight of powder = 14.96g
Percentage retained =
Powder retained on each sieve
                                                    X 100
Initial weight
Percentage retained = 99.60%
Inference:
From the particle size analysis, it is concluded that almost 99.60 % of the drug passes
through all sieves. Thus the particle size of the API was found to be moderately coarse powder.
B. DRUG- EXCIPIENT COMPATIBILITY STUDIES:
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The following Table No: 35, illustrates the drug – excipient compatible studies.
I. Physical compatibility studies:
Table No: 35 Drug - Excipient physical compatibility studies:
* NCC- No Characteristic Change
II. FT-IR compatibility studies:
Storage condition
/ duration
S.No Composition details Initial
(400C / 75%RH) /
30days
Comments
1 API ( Bisacodyl ) White to off white
crystalline  powder
NCC Compatible
2  API+ Dibasic
calcium phosphate
Off White crystalline
Powder
NCC Compatible
3 API + Kaolin Light brown
crystalline Powder
NCC Compatible
4 API + Lactose Off White crystallinePowder
NCC Compatible
5 API + Starch Off White  crystalline
Powder
NCC Compatible
6. API + CCS White  crystalline
Powder
NCC Compatible
7. API + PVP Off White  crystalline
Powder
NCC Compatible
8. API + SLS Off White  crystalline
Powder
NCC Compatible
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The FT-IR studies of pure bisacodyl and individual excipients with bisacodyl  were
carried out to study the interaction between the drug and excipients. The analysed FT-IR
spectra and interpretation data for the drug sample and the drug- excipient mixtures were
shown in the Figure No:7,8,9,10,11,12,13,14 and  Table No: 36, 37, 38,39, 40, 41 and 43.
Figure No: 7
FT-IR spectrum of bisacodyl pure drug
Table No: 36
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Interpretation of  Bisacodyl Pure Drug
Wave number ( cm-1) Signal assignment
1586.78 C-C Stretching
1504.28 -C=C Stretching
1435.00 C-C Aromatic stretching
1370.00 C-H Alkane rocking
1218.64 C-N Aromatics stretching
1010 -C-O Stretching
Figure No: 8
FT-IR spectrum of bisacodyl with dibasic calcium phosphate
Table No: 37
RESULTS AND DISCUSSION
Department of Pharmaceutics Page 108
Interpretation of bisacodyl with dibasic calcium phosphate
Wave number ( cm-1) Signal assignment
1755.47 C=O Ester stretching
1372.41 C-H Aldehyde deformation
1586.80 C=C Aromatic stretching
854.90 =C-H Alkene bending
1432.48 C-H Alkane bending
665.37 C-H Wagging
565.50 C-C Skeletal vibration
Figure No: 9
FT-IR spectrum of bisacodyl with kaolin
Table No: 38
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Interpretation of bisacodyl with kaolin
Wave number ( cm-1) Signal assignment
1586.76 C-C Stretching
1507.19 -C=C Alkene stretching
1374.19 C-H Alkane rocking
1213.24 C-N Aromatic stretching
987.52 -C-O Stretching
Figure No: 10
FT-IR spectrum of bisacodyl with lactose
Table No: 39
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Interpretation of bisacodyl with lactose
Wave number ( cm-1) Signal assignment
1757.24 C=O Carbonyl stretching
3554.06 N-H Amine stretching
3608.30 O-H Stretching
1372.52 C=C Stretching
665.44 C-H Wagging
1586.96 C=C Stretching
Figure No: 11
FT-IR spectrum of bisacodyl with starch
Table No: 40
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Interpretation of bisacodyl with starch
Wave number ( cm-1) Signal assignment
3665.72 O-H Alcohol free stretching
3450.20 O-H Alcohol broad stretching
1208.58 C-N Amine stretching
1758.71 C=O Stretching
1373.24 C=C Aromatic deformation
915.04 C-O Stretching
Figure No: 12
FT-IR spectrum of bisacodyl with croscarmellose sodium
Table No: 41
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Interpretation of bisacodyl with croscarmellose sodium
Wave number ( cm-1) Signal assignment
1580.00 C-C Stretching
1505.07 -C=C Stretching
1440.00 C-C Aromatic stretching
1370.00 C-H Alkane rocking
1211.37 C-N Aromatic stretching
665.49 C-H Rocking
Figure No: 13
FT-IR spectrum of bisacodyl with polyvinyl pyrrolidione
Table No: 42
Interpretation of bisacodyl with polyvinyl pyrrolidione
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Wave number ( cm-1) Signal assignment
1756.47 C=O Ester stretching
1505.75 -C=C Stretching
1370.00 C-H Alkane rocking
1213.24 C-N Aromatic stretching
1017.6 -C-O Stretching
751.91 Benzene ring stretching
Figure No: 14
FT-IR spectrum of bisacodyl with sodium lauryl sulphate
Table No: 43
Interpretation of bisacodyl with sodium lauryl sulphate
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Wave number ( cm-1) Signal assignment
2915.03 C-H Stretching
3394.47 O-H Alcohol stretching
1220.84 C-H deformation
1756.68 C=O Carbonyl stretching
1506.71 C=C Aromatic stretching
EVALUATION OF PRE COMPRESSION PARAMETERS FOR POWDER BLEND:
The pre compression parameters for the powder blend or granules were evaluated
as per procedure mentioned in the methodology part and the results were tabulated in
Table No: 44 and 45.
Table No:44
Pre - Compression parameters for powder blend
*All the values are mean ±SD, n=3
Table No: 45
Sieve analysis for the powder blends of formulations (F1 – F7)
CODE Bulk
density *
(g/ml)
 Tapped
 density *
(g/ml)
Compresibility
   Index *
     (%)
Hausner’s
Ratio *
  Moisture
  Content
      (%)
F1 0.376±0.007 0.430±0.005 12.49±0.007 1.14±0.002 1.58%
F2 0.380±0.001 0.464±0.002 18.14±0.006 1.22±0.001 1.39%
F3 0.382±0.001 0.449±0.004 14.99±0.009 1.17±0.006 1.54%
F4 0.387±0.007 0.471±0.003 17.83±0.004 1.21±0.007 1.66%
F5 0.386±0.002 0.461±0.002 15.70±0.002 1.17±0.007 1.22%
F6 0.378±0.001 0.408±0.006 7.50±0.001 1.08±0.009 1.05%
F7 0.374±0.005 0.394±0.002 4.99±0.007 1.05±0.007 0.92%
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% RetainedSieve No.
(#)
Sieve
aperture
(µm) F1 F2 F3 F4 F5 F6 F7
20 850 2.39 1.27 0.69 2.19 0.39 3.18 1.58
40 425 17.80 10.23 7.70 12.98 8.71 21.11 8.98
60 250 43.15 20.51 26.46 39.95 24.18 40.83 23.75
100 150 77.68 65.61 58.20 76.90 51.07 83.86 55.88
Pan …. 96.00 99.28 98.72 99.36 98.64 99.60 99.50
Inference:
The result of flow properties of prepared granules of various formulations of bisacodyl
were given in  the Table No: 44 and 45. Flow properties of the granules, resistance to particle
movement can be judged from the bulk density, tapped density, compressibility index,
hausner’s ratio. This measurement gives qualitative and quantitative assessment of internal
cohesive and frictional force under low levels of external loading as might be applied in
mixing and tableting. The bulk density was found within the range of 0.374 to 0.382 g/ml. The
tapped density was found within the range of 0.394 to 0.471 g/ml. using the density data,
hausner’s ratio and compressibility index was calculated. The hausner’s ratio was found
within the ranges of 1.05 to 1.22 which indicates better flowability. The Compressibility index
was found within the ranges of 4.99 to 18.14% , indicating good flow properties.
EVALUATION OF POST COMPRESSION PARAMETERS FOR COMPRESSED
TABLETS:
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The post compression parameters were evaluated for the core and enteric- coated
tablets and the results were tabulated in Table No: 46 and 47.
Table No: 46
Evaluation of post- compression parameters for core tablets
CODE General
appearance
Weight
variation
(mg)
Thickness*
(mm)
Friability*
(%)
Hardness*
(kg/cm2)
Disintegration
Time #
(minutes)
F1 Round,
Convex
120±0.5 2.87±0.01 0.28±0.09 7.0±0.2 7min 45sec
±0.011
F2 Round,
Convex
120±0.5 2.95±0.02 0.35±0.02 6.5±0.1 8min10sec
±0.056
F3 Round,
Convex
100±0.6 3.02±0.10 1.32±0.03 6.0±0.2 7min 15sec
±0.018
F4 Round,
Convex
100±0.3 3.00± 0.08 0.19±0.04 5.3±0.3 6min 10sec
±0.052
F5 Round,
Convex
100±0.2 3.09±0.03 0.24±0.05 6.5±0.3 9min 50sec
±0.031
F6 Round,
Convex
100±0.9 3.10±0.04 0.15±0.02 4.0±0.8 5min 10sec
±0.045
F7 Round,
Convex
100±0.1 3.20±0.05 0.10±0.01 3.0±0.2 2min 17sec
±0.021
*All the values are mean ±SD, n=3
#All the values are mean ±SD, n=6
Figure No: 15
Profile of hardness for various formulations ( F1- F7)
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Figure No: 16
Profile of friability for various formulations ( F1- F7)
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Figure No: 17
RESULTS AND DISCUSSION
Department of Pharmaceutics Page 118
Profile of Thickness for various formulations ( F1- F7)
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Table No: 47
Invitro dissolution data for the core tablets in pH-7.4 buffer medium at 45mins
Time F1 F2 F3 F4 F5 F6 F7
45 mins 74.25% 79.20% 83.30% 85.95% 80.10% 89.62% 93.98%
Tolerances:
Not less than 70% of the labelled amount of bisacodyl dissolved in 45 minutes
Figure No: 18
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Invitro Dissolution profile of core tablets for various formulations ( F1- F7)
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Table No: 48
Evaluation of post-compression parameters for enteric coated tablets
Code
Average
Weight*
( mg )
Thickness
(mm)*
Hardness*
(Kg/cm2)
Disintegration
Time #
(minutes)
Assay
(%)*
F7 109.15±0.04 3.14±0.03 4.0±0.1 6min23sec
± 0.02
99.92 ±
0.08
*All the values are mean ±SD, n=3
#All the values are mean ±SD, n=6
Table No: 49
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Invitro dissolution profile for the innovator product and
formulation (F7)
Dissolution medium Sampling time % Drug release
Innovator F7
Simulated gastric fluid (0.1N
HCL)
120 minutes 0.276% 0.055%
Simulated intestinal fluid
( pH 7.4 phosphate buffer)
45 minutes 87.37% 90.74%
Limits:
 The amount of bisacodyl released in case of simulated gastric fluid
(0.1 N HCL) is Not More Than 5% of the stated amount.
 The amount of bisacodyl released in case of simulated intestinal fluid
(pH 7.4)  is Not Less Than 75% (Q) of the stated amount.
Comparative Invitro dissolution study using similarity factor:
Table No: 50
Invitro dissolution profile comparison using similarity factor for the
innovator  product with the sample (F7)
Time
(mins)
Reference( R) Test (T) RT – TT (RT – TT) 2 |RT-TT |
0 0.00 0.00 0.00 0.00 0.00
15 31.37 33.55 - 2.18 4.752 2.18
30 63.73 67.03 -3.3 10.890 3.3
45 87.37 90.74 -3.37 11.356 3.37
Inference:
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On  substituting the observed values in the appropriate formula, the difference factor(f1)
and the similarity factor(f2) was found to be 5.32 and 75.08.
Figure No: 19
Comparative  Invitro dissolution profile for the innovator with formulation (F7)
ASSAY:
The assay determination for the blank, standard and sample was carried out by the
HPLC method.
Standard chromatogram of bisacodyl:
The  peak  area  plot of bisacodyl standard chromatogram is given in the figure no:20.
Figure No: 20
Standard chromatogram of Bisacodyl
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Sample Chromatogram:
The  peak  area  plot of sample chromatogram is given in the figure no:21.
Figure No: 21
Sample chromatogram
0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 min
-25
0
25
50
75
100
125
150
175
200
225
250
mAU
265nm,4nm (1.00)
Bi
sa
co
dy
l /2
.9
98
/1
52
18
14
Blank chromatogram:
The  peak  area  plot of  bisacodyl blank chromatogram is given in the figure no:22.
Name Retention
time
Area Tailing factor Theoretical
Plate
Bisacodyl 2.9 1268094 1.24 4643.3
Name Retention
time
Area Tailing factor Theoretical
Plate
Bisacodyl 2.9 1521814 1.23 4709.6
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Figure No:22
 Blank chromatogram
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STABILITY STUDIES:
Table No: 51
Accelerated stability data of  physical parameters for the formulation (F7)
*All the values are mean ±SD, n=3
Storage conditions
40˚C±2˚C / 75% RH±5% RH
Physical
parameters
Initial 1st month 2nd month 3rd month
Description  Pale yellow, round
enteric coated
tablet
Pale yellow, round
enteric coated
tablet
 Pale yellow, round
enteric coated
tablet
 Pale yellow, round
enteric coated
tablet
Avg.weight*
(mg)
109.15±0.04 109.21±0.02 109.55±0.04 109.89±0.01
Hardness*
(kg/cm2)
4.0±0.1 3.8±0.2 4.2±0.1 3.5±0.15
Thickness*
(mm)
3.14±0.03 3.14±0.08 3.15±0.01 3.14±0.05
Disintegration
time
6min23sec
± 0.02
6min 40sec
± 0.02
7min 10sec
± 0.05
6min 89sec
± 0.07
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Table No: 52
Accelerated stability data of Invitro dissolution and assay for the
 formulation (F7)
Storage conditions
40˚C±2˚C / 75% RH±5% RH
Parameters Specifications
Initial 1st
month
2nd
month
3rd
month
Simulated gastric fluid
(0.1N HCL)
NMT 5%
in 120minutes 0.055% 0.063% 0.087% 0.109%
Simulated intestinal fluid
( pH 7.4 phosphate buffer) NLT 75% in
45 minutes
90.74% 89.95% 89.18% 88.69%
Assay (%) 95.0 to
105.0%
99.92% 99.54% 98.61% 89.87%
Inference:
The formulation (F7) of enteric coated tablets were carried out for the accelerated
stability studies for 3 months at 40˚C±2˚C / 75% RH±5% RH in the stability chamber.
The resulted data’s are given in the Table No: 51 and 52. The results reveals that no
significant changes in the physical parameters  at the end of 1st, 2nd,3rd month. The drug
content and in vitro dissolution profile are remained with out any significant changes, at
the end of 1st, 2nd, 3rd month. Hence it is concluded that the formulated enteric coated tablets
are stable and the data obtained could be used to predict the shelf life of the product.
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DISCUSSION
The present aim of the work is to develop and formulate the stable  bisacodyl enteric
coated tablets and to comply the invitro dissolution parameters with the innovator product.
As per British pharmacopoeial specifications (BP 2013), the bisacodyl tablets should
comply the invitro dissolution test as prescribed in the monograph. As per specifications,
amount of bisacodyl released in the dissolution  medium is  Not More Than  5% in case of
acid medium and  Not Less Than 75% (Q) of the stated amount in case of pH 7.4 phosphate
buffer medium.
Since bisacodyl is an highly acid liable drug, it is necessary to formulate the tablet as
enteric coated tablets which resists the drug releasing in the stomach.
In this work, all the core tablets were formulated by wet granulation method by using
povidone as binder. Aqueous coating is performed for the both seal and enteric coating
process.
The present work was initiated with the preformulation studies for the API  and
evaluating the parameters like description, solubility analysis, moisture content, micromeritic
properties and particle size determination. The evaluating in-process parameters for the
powder blend are bulk density, tapped density, compressibility index, moisture content and
hausner’s ratio. The compressed tablets were evaluated for the parameters like thickness,
hardness, friability, assay and invitro dissolution study.
The impacts observed from the various in-process parameters for the powder blends
and compressed tablets were discussed one by one below.
PRE FORMULATION STUDIES:
Evaluation of Active Pharmaceutical Ingredient (API):
The preformulation studies for the API reveals that the description of  the bisacodyl
powder was appeared as white crystalline and  has no odour. Based on the solubility analysis,
the API was found to be  insoluble in water where as soluble in acetone and isopropyl alcohol .
The moisture content was found to be 0.96% at 600C. The micromeritic properties of API was
found to be satisfactory and it shows an moderate flow properties. The particle size
determination was performed  by sieving method. It shows that almost 99.60% of the drug
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passes through all the sieves and it is an moderately coarse powder. From the drug- excipients
compatibility study, it was observed that there was no significant change or interaction
between drug and excipients on storage conditions at 400C / 75%RH for 2 weeks.
EVALUATION  PARAMETERS:
I. Evaluation of Pre Compression parameters for Powder Blend:
The results of evaluation of powder blends for all the formulations (F1 to F7) were
given in the Table No:44 and 45, it suggests that it has good flow property. The bulk  density
values observed from the formulations F1 to F7 was found to be within the range 0.374 to
0.387g/ml. The formulation F7 shows lowest value when compared to other formulations. The
tapped  density values observed from the formulations F1 to F7 was found to be with in range
0.374 to 0.464g/ml. Settling down of granules for F1 to F5 is difficult when tapping whereas
F6 and F7 formulation is not difficult.  The compressibility index for the formulations F1 to F5
was found to be with in range 12.49 to 18.14 % which shows fair flow in granules whereas
formulation F6 and F7 shows good flow characters when compared to other five formulations.
The hausner’s ratio for the formulations F1 to F7 was found within the range 1.05 to 1.22.
From the observed values the flow type was good for all formulations.
II. Evaluation of Post Compression parameters for core tablets :
The results of compressed core tablets  were given in the Table No:46 and 47 All the
formulation batches of core tablets shows good in appearance.
In the formulation F1, with the presence of diluents- kaolin(10.83%) , lactose
anhydrous(40.83%)  were added in intra and extra granular part , starch(26.6%), and povidone
(2.5%), it shows that  hardness of tablets was found to be 7.0 (kg/cm2) and drug release is only
74.25% in the buffer medium. Due to low drug release initially, if coated this will tends to
decrease more and fails the limits. So the next trial is taken with the improvement in
solubility.
In the formulation F2, with the incorporation of dibasic calcium phosphate (8.33%)
and slightly increasing the percentage concentration of kaolin and starch, removing the lactose
anhydrous from extra granular part, the hardness of tablets shows 6.5 (kg/cm2) only an slight
difference and drug release was found to be 79.20%  in the buffer medium.
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In the formulation F3, inclusion of  1% sodium lauryl sulphate as wetting agent and
lactose anhydrous (27%) and povidone (3%) where friability failed in this batch.
In the formulation F4, removing sodium lauryl sulphate and starch were removed,
instead micro crystalline cellulose (20%), DCP (19%) and kaolin (25%)were added. The
disintegration time was found to be 6mins 10sec, an little faster when compared to other three
trials. In this trial, tablets friability have passed. The drug release was found to be better when
compared with previous batches (85.95%). In this trial, lot of materials sticked to the meshes it
may be due to kaolin at increasing concentration.
In the formulation F5, lactose is removed and  starch (20%), micro crystalline cellulose
(27%), Dibasic calcium phosphate (19%) and Kaolin( 18%) were added, disintegration time
was found to be 9mins 50sec and drug release  also reduced to 80.10% when compared to
previous trial. Since harder tablet is formed in this trial, further trial is taken to reduce the
hardness.
In the formulation F6, sodium lauryl sulphate at 0.3% concentration and  lactose (27%)
were incorporated and micro crystalline cellulose is removed where the tablets disintegration
time was found to be 5min 10sec, an little improvement and the drug release was found to be
89.62%. Trial 6 show better dissolution in pH 7.4 buffer medium, hence keeping ‘F6’ as base
formula further trial is taken.
In the formulation F7, The tablet shows good mechanical strength and the disintegrating
time was found to be 2min 17sec. The drug release was found to be 93.98% in pH7.4 phosphate
buffer medium.
In all the formulations from F1 to F7, croscarmellose sodium were used as the
disintegrant  and povidone K-30 used as an binder.
Based on disintegration time and drug release values observed for the various
formulations,  F7 shows good disintegration time and drug release in the buffer medium.
RESULTS AND DISCUSSION
Department of Pharmaceutics Page 128
F7 formulation core tablet shows satisfactory analytical results and hence decided to
enteric coat the core tablet with 2% seal coating and 7% enteric coating  with the poly
methacryllic acid methyl acrylate as polymer.
III. Evaluation of Post-compression Parameters for Enteric Coated Tablet:
The optmized formulation (F7) were subjected to coating with 2% seal coating with the
hydroxypropyl methyl cellulose 15-cps as polymer and 7 % enteric- coating with  the poly
methacryllic acid methyl acrylate as polymer. The results for the evaluated parameters were
given in the Table No: 48 and 49. The thickness of the tablet was found to be 3.14mm and
hardness is 4.0 kg/cm2. The % drug content was found to be 99.92% which is acceptable under
the limits. The % drug release was found to be 0.055% in the acid medium and 90.74% in the
buffer medium which is acceptable limits as per monograph.
IV. Comparative Invitro dissolution study:
The Invitro dissolution profile of formulation (F7) and the innovator product were
compared by calculating the differential factor (f1) and similarity factor (f2). The results were
tabulated in Table No: 50, and the factors f1 and f2 was found to be 5.32 and 75.08,
respectively which is an acceptable limits. Hence the two products were considered as similar
and comparable.
V. Stability studies:
Accelerated stability studies were carried out for the optimized formulation (F7)
enteric coated tablets. 20 tablets were packed in blister packing and loaded in the stability
chamber for 3 months at 40˚C±2˚C / 75% RH±5% RH. The resulted data’s are given in the
Table No:51 and 52. No significant changes was observed in the physical parameters, drug
release and drug content when stored at 40˚C±2˚C / 75% RH±5% RH for 3 months. The drug
release was found to be 88.68% in the buffer medium and the drug content is 89.87% were
satisfies the pharmacopoeial limits. Hence it is concluded that the formulated enteric coated
tablets were stable.
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8. CONCLUSION
The present study involves to design and formulate the enteric - coated tablets of
bisacodyl and to comply the invitro dissolution data as per BP specifications.
Preformulation studies has been performed to study the nature of API and
compatibility of API with excipients by physical observation and FT-IR studies. The results
showed that there was no interaction between API and  all the excipients selected.
Enteric coated tablets of bisacodyl were successfully formulated by wet granulation
method using the selected excipient with required quantities. The formulated tablets were
evaluated for both pre-compression and post-compression parameters like bulk density,
tapped density, compressibility index, hausner’s ratio, moisture content, hardness, thickness,
disintegration time and invitro dissolution and assay as per requirements of  standards.
The results were found to be satisfactory with the pharmacopoeial specifications.
Among all the entire batches, formulation (F7) is the best formulation which
complies all the pharmacopoeial specifications. The best formulation is selected  based on
the invitro dissolution data when compared with that of innovator product using the
similarity factor.
The most satisfactory formulation has been subjected to Accelerated stability studies
as per ICH guidelines for 3 months at 40˚C±2˚C / 75% ±5% RH. The results of stability
studies shows no significant changes in the physical parameters of the tablets, drug content
and invitro dissolution data until the end of 3 months from the initial values. Hence it is
concluded that the formulated bisacodyl enteric coated tablets were stable and this study
fulfilled all the pharamcopoeial specifications.
Future study:
The present work may explore the following  aspects  in the future, which may become a
valuable assets in the field of pharmaceutical science.
1. Accelerated stability study is continued for another 3months and shelf life is
determined.
2. Scale up activity of the optimized formulation.
3. The invitro studies can be extended to invivo studies by leading to a final conclusion
of a successful formulation which can be marketed there after.
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